WO2023099620A1 - Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes - Google Patents

Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes Download PDF

Info

Publication number
WO2023099620A1
WO2023099620A1 PCT/EP2022/083950 EP2022083950W WO2023099620A1 WO 2023099620 A1 WO2023099620 A1 WO 2023099620A1 EP 2022083950 W EP2022083950 W EP 2022083950W WO 2023099620 A1 WO2023099620 A1 WO 2023099620A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
kras
cancer
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2022/083950
Other languages
English (en)
French (fr)
Inventor
Joachim BROEKER
Alessio CIULLI
Emelyne DIERS
Andreas Gollner
Jake GOODWIN-TINDALL
William Farnaby
Christiane Kofink
Andreas Mantoulidis
Ross MCLENNAN
Johannes Popow
Martin SCHMIEDEL
Nicole TRAINOR
Harald WEINSTABL
Siying ZHONG
David ZOLLMAN
Jason ABBOTT
Jianwen Cui
Stephen W. Fesik
Andrew Little
Dhruba Sarkar
Alex WATERSON
Christian Alan Paul Smethurst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Vanderbilt University
Original Assignee
Boehringer Ingelheim International GmbH
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Vanderbilt University filed Critical Boehringer Ingelheim International GmbH
Priority to CN202280089389.4A priority Critical patent/CN118591540A/zh
Priority to US18/715,145 priority patent/US20250145608A1/en
Priority to JP2024532456A priority patent/JP2024542692A/ja
Priority to EP22826087.3A priority patent/EP4441051A1/en
Publication of WO2023099620A1 publication Critical patent/WO2023099620A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present invention relates to compounds and derivatives of formula (I): wherein R 1a , R 1b , R 2a , R 2b , Z, R 4 , ring A, R 5 , m, U, V, W, ring B, L, X, Y, R 9 , R 10 , q, R 6 and R 7 have the meanings given in the claims and specification, their use as degraders of KRAS, pharmaceutical compositions comprising the same and their medical uses, especially as agents for treatment and/or prevention of oncological diseases.
  • V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog is a small GTPase of the Ras family of proteins that exists in cells in either GTP-bound or GDP-bound states (McCormick et a/., J. Mol. Med. (Berl)., 2016, 94(3):253-8; Nimnual et a!., Sci. STKE., 2002, 2002(145) :pe36). Binding of GTPase activating proteins (GAPs) such as NF1 increases the GTPase activity of Ras family proteins.
  • GAPs GTPase activating proteins
  • GEFs guanine nucleotide exchange factors
  • Ras family proteins When in the GTP-bound state, Ras family proteins are active and engage effector proteins including C-RAF and phosphoinositide 3-kinase (PI3K) to promote the RAF/mitogen or extracellular signal-regulated kinases (MEK/ERK) pathway, PI3K/AKT/mammalian target of rapamycin (mTOR) pathway and RaIGDS (Rai guanine nucleotide dissociation stimulator) pathway (McCormick et al., J. Mol. Med. (Berl)., 2016, 94(3):253-8; Rodriguez-Viciana et al., Cancer Cell. 2005, 7(3):205-6).
  • PI3K C-RAF and phosphoinositide 3-kinase
  • Ras family proteins suppress their intrinsic and GAP- induced GTPase activity leading to an increased population of GTP-bound/active mutant Ras family proteins (McCormick et al., Expert Opin. Ther. Targets., 2015, 19(4):451-4; Hunter et al., Mol. Cancer Res., 2015, 13(9): 1325-35). This in turn leads to persistent activation of effector pathways (e.g. RAF/MEK/ERK, PI3K/AKT/mTOR, RaIGDS pathways) downstream of mutant Ras family proteins.
  • effector pathways e.g. RAF/MEK/ERK, PI3K/AKT/mTOR, RaIGDS pathways
  • KRAS mutations e.g. amino acids G12, G13, Q61 , A146 are found in a variety of human cancers including lung cancer, colorectal cancer and pancreatic cancer (Cox et al., Nat. Rev. Drug Discov., 2014, 13(11):828-51). Alterations (e.g. mutation, over-expression, gene amplification) in Ras family proteins/Ras genes have also been described as a resistance mechanism against cancer drugs such as the EGFR antibodies cetuximab and panitumumab (Leto et al., J. Mol. Med. (Berl).
  • KRAS proto-oncogene acts as a driver alteration and renders tumor models bearing this genotype addicted to KRAS in vitro and in vivo (Wong et al. Nat Med., 2018, 24(7): 968-977).
  • nonamplified KRAS WT cell lines are KRAS independent, unless they carry secondary alterations in genes indirectly causing activation of KRAS (Meyers et al., Nat Genet., 2017, 49:1779-1784). Based on these data, a therapeutic window is expected for a KRAS targeting agent with a KRAS WT targeting activity.
  • codon 12 of KRAS substitute the glycine residue naturally occurring at this position for different amino acids such as aspartic acid (the G12D mutation or KRAS G12D), cysteine (the G12C mutation or KRAS G12C), valine (the G12V mutation or KRAS G12V) among others.
  • mutations within codons 13, 61 and 146 of KRAS are commonly found in the KRAS gene. Altogether KRAS mutations are detectable in 35 % of lung, 45% of colorectal, and up to 90% of pancreatic cancers (Herdeis et al., Curr Opin Struct Biol., 2021 , 71 :136-147).
  • PROTACs Proteolysis targeting chimeras bind to proteins causing their degradation by inducing their ubiquitination.
  • PROTACs are tripartite or heterobifunctional molecules consisting of a part binding to the protein that is to be degraded, a second part that binds to and can artificially recruit an E3 ubiquitin ligase, and a linker that connects the two parts. Whenever a trimeric complex consisting of the target protein, the PROTAC, and the ligase is formed, the close proximity of the ligase to the target results in target protein ubiquitination.
  • Ubiquitination acts as a posttranslational modification of proteins causing, among others, their recruitment to the proteasome resulting in proteolytic degradation.
  • the multi-ubiquitin chain on the target protein is then recognized by the proteasome and the target protein is degraded (Collins, I. et al., Biochem J., 2017, 474, 1127-1147; Hughes, S.J. and Ciulli, A, Essays Biochem., 2017, 61 , 505-516; Toure, M. and Crews, C.M., Angew. Chem. Int. Ed. Engl., 2016, 55, 1966-1973).
  • PROTAC driven degradation functions in a sub-stoichiometric nature thus requiring lower systemic exposures to achieve efficacy (Bondeson, D.P. et al., Nat. Chem. Bio., 2015, 11 , 611 ; Winter, G.E. et al., Science, 2015, 348, 1376-1381).
  • PROTACs have been shown to display higher degrees of selectivity for protein degradation than the target ligand itself due to complementarity differences in the protein-protein-interaction interfaces of the formed ternary complexes (Bondeson, D.P. et al., Cell Chemical Biology, 2018, 25, 78-87. e75; Gadd, M.S. et al.
  • PROTACs promise to expand the druggable proteome as degradation is not limited to the protein domain functionally responsible for the disease. In the case of challenging multidomain proteins, traditionally viewed as undruggable targets, the most ligandable domain can be targeted for degradation independent of its functionality or vulnerability to small molecule blockade (Gechijian, L.N. et al., Nat. Chem. Bio., 2018, 14, 405-412).
  • KRAS G12C protein which only constitutes a fraction of the whole complement of KRAS mutant tumors.
  • induced degradation of KRAS has the potential to enable irreversible inhibition of KRAS signaling for most remaining KRAS mutations/alterations driving tumor growth provided they can be bound by a heterobifunctional degrader molecule.
  • degraders of wild-type e.g. amplified or overexpressed
  • mutated KRAS e.g. G12C, G12D, G12V, G13D
  • KRAS degrading KRAS
  • Such compounds would be useful in the treatment of a cancer dependent on or mediated by KRAS, especially KRAS mutated in position 12 or 13 and/or in wild-type amplified KRAS mediated cancer, which also possess desirable pharmacological properties, including but not limited to: metabolic stability, plasma protein binding, solubility and permeability.
  • compounds of the present invention have additional advantages.
  • compounds of formula (I) as herein defined can act as degraders of KRAS.
  • the compounds described herein have been found to possess antitumour activity.
  • the compounds of the invention are effective against wildtype (e.g. amplified or overexpressed) as well as mutant KRAS, e.g. G12C, G12D, G12V, G13D.
  • mutant KRAS e.g. G12C, G12D, G12V, G13D.
  • they can be effective against a panel of KRAS mutated forms.
  • the compounds of the invention may be used for example for the treatment of diseases mediated by KRAS and/or characterised by excessive or abnormal cell proliferation.
  • the compounds of the invention advantageously possess desirable pharmacological properties, including but not limited to: metabolic stability, plasma protein binding, solubility and permeability.
  • R1a and R1b are both independently selected from the group consisting of hydrogen, C1-4alkyl, C1-4haloalkyl, C1-4alkoxy, C1-4haloalkoxy, halogen, -NH2, -NH(C1-4alkyl), -N(C1-4alkyl)2, C3-5cycloalkyl and 3-5 membered heterocycloalkyl;
  • R2a and R2b are both independently selected from the group consisting of hydrogen, C1-4alkyl, C1-4haloalkyl, C1-4alkoxy, C1-4haloalkoxy, halogen, -NH2, -NH(C1-4alkyl), -N(C1-4alkyl)2, C3-5cycloalkyl and 3-5 membered heterocycloalkyl; and/or, optionally, one of R1a or R1b and one of R2a or R2b together with the carbon atoms they are attached to form a cycl
  • R 9 is C1-4 alkyl
  • R 10 is selected from the group consisting of hydrogen, Ci-ealkyl, Ci-ealkoxy, -C(O)R 12 and -C(O)OR 12 , wherein said Ci ⁇ alkyl is optionally substituted by -OH or -OP(O)(OH)2; each R 12 is independently hydrogen or Ci ⁇ alkyl; q is selected from the group consisting of 0, 1 and 2; each R 6 , if present, is independently at each occurrence halogen or Ci ⁇ alkyl;
  • R 7 is selected from the group consisting of halogen, Ci ⁇ alkyl, -CN and 5 membered heteroaryl, wherein said 5 membered heteroaryl comprises at least one nitrogen atom and is optionally substituted with R 8 ;
  • R 8 is Ci ⁇ alkyl or Ci-shydroxyalkyl; or a salt thereof.
  • the compound or salt of formula (I) is of formula (I*): wherein R 1a , R 1b , R 2a , R 2b , Z, R 4 , ring A, R 5 , m, U, V, W, ring B, L, X, Y, R 9 , R 10 , q, R 6 and R 7 are as herein defined.
  • the compound or salt of formula (I) is of formula (I**): wherein R 1a , R 1b , R 2a , R 2b , Z, R 4 , ring A, R 5 , m, U, V, W, ring B, L, X, Y, R 9 , R 10 , q, R 6 and R 7 are as herein defined.
  • the compound or salt of formula (I) is of formula (I***): wherein R 1a , R 1b , R 2a , R 2b , Z, R 4 , ring A, R 5 , m, U, V, W, ring B, L, X, Y, R 9 , R 10 , q, R 6 and R 7 are as herein defined.
  • R 1a , R 1b , R 2a , R 2b , Z, R 4 , ring A, R 5 , m, U, V, W, ring B, L, X, Y, R 9 , R 10 , q, R 6 and R 7 are as herein defined.
  • the compound of formula (I) is of formula (la): wherein R 1a , R 1b , R 2a , R 2b , Z, R 4 , U, V, W, ring B, L, X, Y, R 9 , R 10 , q, R 6 , R 7 and the stereochemistry are as herein defined.
  • the stereochemistry at the chiral centres in formula (la) is as defined in any one of formulas (I*), (I**), (I***) or (I****).
  • the compound of formula (I) is of formula (lb): wherein R 1a , R 1b , R 2a , R 2b , Z, R 4 , U, V, W, ring B, L, X, Y, R 9 , R 10 , q, R 6 , R 7 and the stereochemistry are as herein defined.
  • the stereochemistry at the chiral centres in formula (lb) is as defined in any one of formulas (I*), (I**), (I***) or (I****).
  • the compound of formula (I) is of formula (Ic): wherein R 1a , R 1b , R 2a , R 2b , Z, R 4 , U, V, W, ring B, L, X, Y, R 9 , R 10 , q, R 6 , R 7 and the stereochemistry are as herein defined.
  • the stereochemistry at the chiral centres in formula (Ic) is as defined in any one of formulas (I*), (I**), (I***) or (I****).
  • the compound of formula (I) is of formula (Id):
  • R 1a , R 1b , R 2a , R 2b , Z, R 4 , U, V, W, ring B, L, X, Y, R 9 , R 10 , q, R 6 , R 7 and the stereochemistry are as herein defined.
  • the stereochemistry at the chiral centres in formula (Id) is as defined in any one of formulas (I*), (I**), (I***) or (I****).
  • the compound of formula (I) is of formula (le): wherein R 1a , R 1b , R 2a , R 2b , Z, R 4 , U, V, W, ring B, L, X, Y, R 9 , R 10 , q, R 6 , R 7 and the stereochemistry are as herein defined.
  • the stereochemistry at the chiral centres in formula (le) is as defined in any one of formulas (I*), (I**), (I***) or (I****).
  • the compound of formula (I) is of formula (If): wherein R 1a , R 1b , R 2a , R 2b , Z, R 4 , ring A, R 5 , m, U, V, W, ring B, L, X, R 9 , R 10 , q, R 6 , R 7 and the stereochemistry are as herein defined.
  • the stereochemistry at the chiral centres in formula (If) is as defined in any one of formulas (I*), (I**), (I***) or (I****).
  • the compound of formula (I) is of formula (Ig): wherein R 1a , R 1b , R 2a , R 2b , Z, R 4 , ring A, R 5 , m, U, V, W, ring B, L, X, R 9 , R 10 , q, R 6 , R 7 and the stereochemistry are as herein defined.
  • the stereochemistry at the chiral centres in formula (Ig) is as defined in any one of formulas (I*), (I**), (I***) or (I****).
  • the compound of formula (I) is of formula (Ih): wherein R 1a , R 1b , R 2a , R 2b , Z, R 4 , ring A, R 5 , m, U, V, W, ring B, L, X, R 9 , R 10 , q, R 6 , R 7 and the stereochemistry are as herein defined.
  • the stereochemistry at the chiral centres in formula (Ih) is as defined in any one of formulas (I*), (I**), (I***) or (I****).
  • compounds of formula (I*), (I**), (I***), (I****), (la), (lb), (Ic), (Id), (le), (If), (ig), and (Ih) each are a subset of compounds of formula (I).
  • Any reference to compounds of formula (I) is meant to also refer to and include compounds of each of formulas (I*), (I**), (I***), (I****), (la), (lb), (Ic), (Id), (le), (If), (Ig), and (Ih) unless stated otherwise.
  • Formulas (I*), (I**), (I***), (I****), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), and (Ih) alone or together can be referred to as “subformula” or “subformulas” of formula (I).
  • one of R1a or R1b is hydrogen.
  • R1a and R1b are hydrogen.
  • one of R2a or R2b is hydrogen.
  • R2a and R2b are hydrogen.
  • R1a, R1b, R2a and R2b are hydrogen.
  • R3a or R3b is hydrogen.
  • R3a and R3b are hydrogen.
  • R4 is selected from the group consisting of hydrogen, C1-3alkyl, C1-3haloalkyl, C1-3alkoxy, C1-3haloalkoxy, cyano-C1-3alkyl, halogen, -OH, -NH2, -NH(C1- 3alkyl), -N(C1-3alkyl)2, -CN, C3-4cycloalkyl and 3-4 membered heterocycloalkyl.
  • R4 is C1-6alkyl.
  • R 4 is Ci- 3 alkyl.
  • R 4 is methyl.
  • R 1a , R 1b , R 2a and R 2b are hydrogen, Z is -CH2- and R 4 is methyl.
  • R 1a , R 1b , R 2a and R 2b are hydrogen, Z is -CH2-, R 4 is methyl and the carbon atom to which R 4 and ring A are attached is in the (S) configuration.
  • ring A is selected from the group consisting of pyrrole, furan, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, thiadiazole and triazole.
  • ring A is selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, oxadiazole and thiadiazole.
  • ring A is selected from the group consisting of isoxazole, isothiazole and oxadiazole.
  • ring A is selected from the group consisting of:
  • ring A is selected from the group consisting of:
  • oxadiaziole is selected from the group consisting of In another aspect of the compound of formula (I), (I*), (I**), (I***), (I****), (la), (lb), (Ic), (Id), (le), (If), (Ig), or (Ih), at any occurrence oxadiaziole is selected from the group consisting of In another aspect of the compound of formula (I), (I*), (I**), (I***), (I****), (la), (lb), (Ic), (Id), (le), (If), (ig), or (Ih), at any occurrence oxadiaziole is
  • R 11 is hydrogen
  • V C(H)-
  • W N- and the carbon atom to which R 4 and ring A are attached is in the (S) configuration.
  • ring B comprises at least one nitrogen atom.
  • ring B comprises two nitrogen atoms.
  • ring B is a 3-11 membered heterocycloalkylene substituted with one Ci-ealkyl and optionally further substituted with one or more identical or different Ci-ealkyl, Ci-ealkoxy or a 5-6 membered heterocycoalklyl, wherein any of the Ci-ealkyl is optionally and independently substituted with cyclopropyl, preferably wherein said 3-11 membered heterocycloalkylene comprises at least one nitrogen atom or wherein said 3-11 membered heterocycloalkylene comprises two nitrogen atoms.
  • ring B is a 5-8 membered heterocycloalkylene optionally substituted with one or more identical or different Ci-salkyl, Ci-3alkoxy or a 5-6 membered heterocycloalkyl, wherein the Ci-salkyl is optionally substituted with cyclopropyl, preferably wherein said 5-8 membered heterocycloalkylene comprises at least one nitrogen atom or wherein said 5-8 membered heterocycloalkylene comprises two nitrogen atoms.
  • ring B is a 5-8 membered heterocycloalkylene substituted with one Cisalkyl and optionally further substituted with one or more identical or different Ci-salkyl , Cisalkoxy or a 5-6 membered heterocycloalkyl, preferably wherein said 5-8 membered heterocycloalkylene comprises at least one nitrogen atom or wherein said 5-8 membered heterocycloalkylene comprises two nitrogen atoms.
  • ring B is wherein r is 0, 1 or 2, s is 0, 1 , 2, 3 or 4, R 13 is Ci-ealkyl, each R 14 is independently at each occurrence Ci-ealkyl, Ci-ealkoxy ora 5-6 membered heterocycloalkyl and any of the Ci-ealkyl is optionally substituted with cyclopropyl.
  • ring B is wherein r is 0, 1 or 2, s is 0, 1 , 2, 3 or 4, R 13 is Ci-salkyl, each R 14 is independently at each occurrence Ci ⁇ alkyl , Ci-salkoxy or a 5-6 membered heterocycloalkyl.
  • ring B is , wherein r is 0, 1 or 2, s is 0, 1 or 2, R13 is C 1-3 alkyl and each R14 is independently at each occurrence the same or different C 1-3 alkyl.
  • the carbon atom to which R13 is attached is in the (S) configuration.
  • r is 0 or 1.
  • r is 0.
  • s is 0, 1 or 2.
  • s is 0.
  • s is 1.
  • s is 2.
  • R13 is methyl.
  • R14 is methyl.
  • ring B is wherein p is selected from the group consisting of 0, 1, 2 and 3.
  • ring B is wherein p is 1 or 2 and the chiral carbon atom is in the (S) configuration.
  • ring B is selected from the group consisting of: , .
  • ring B is selected from the group consisting of: It is to be understood that “(C)” and “(L)” indicate the atom or substituent of formula (I) to which ring B is attached.
  • L is selected from the group consisting of C 1-8 alkylene, C 2-8 alkenylene and C 1-8 alkoxylene.
  • L is selected from the group consisting of C 1-6 alkylene, C 2-6 alkenylene and C 1-6 alkoxylene.
  • L is selected from the group consisting of: In another aspect of the compound of formula (I), (I*), (I**), (I***), (I****), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), L is selected from the group consisting of: In another aspect of the compound of formula (I), (I*), (I**), (I***), (I****), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), L is selected from the group consisting of: .
  • L is selected from the group consisting of: , In another aspect of the compound of formula (I), (I*), (I**), (I***), (I****), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), L is selected from the group consisting of: , In another aspect of the compound of formula (I), (I*), (I**), (I***), (I****), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), or (Ih), L is selected from the group consisting of:
  • Y is a 5 membered heteroarylene or -C(O)(NH)-, wherein said 5 membered heteroarylene comprises at least one nitrogen atom and wherein said -C(O)(NH)- is linked to X via the C atom.
  • Y is selected from the group consisting of pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, thiadiazole, triazole and -C(O)(NR 12 )-, wherein said -C(O)(NR 12 )- is linked to X via the C atom, preferably wherein R 12 is hydrogen.
  • Y is selected from the group consisting of pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, thiadiazole and triazole.
  • Y is isoxazole, triazole or -C(O)(NR 12 )-, wherein said -C(O)(NR 12 )- is linked to X via the C atom.
  • Y is isoxazole, triazole or -C(O)(NH)-, wherein said -C(O)(NH)- is linked to X via the C atom.
  • Y is -C(O)(NH)-, wherein said -C(O)(NH)- is linked to X via the C atom.
  • Y is isoxazole or triazole.
  • Y is isoxazole.
  • Y is triazole.
  • Y is selected from the group consisting of:
  • Y is selected from the group consisting of:
  • Y is selected from the group consisting of:
  • triazole is selected from the group consisting of: In another aspect of the compound of formula (I), (I*), (I**), (I***), (I****), (la), (lb), (Ic), (Id), (le), (If), (ig), or (Ih), when Y is -C(O)(NR 12 )-, X is -(CH 2 )-, wherein said -C(O)(NR 12 )- is linked to X via the C atom.
  • X is -(CH 2 )- and Y is -C(O)(NR 12 )-, or X is -(CH 2 )- or -O- and Y is a 5 membered heteroarylene comprising at least one nitrogen atom, wherein said -C(O)(NR 12 )- is linked to X via the C atom.
  • X is -(CH 2 )- and Y is -C(O)(NR 12 )-, wherein said -C(O)(NR 12 )- is linked to X via the C atom.
  • X is -(CH 2 )-
  • Y is -C(O)(NR 12 )-, wherein said -C(O)(NR 12 )- is linked to X via the C atom and L is Ci-salkylene or a Ci-salkoxylene.
  • X is -(CH 2 )-
  • Y is -C(O)(NR 12 )-, wherein said -C(O)(NR 12 )- is linked to X via the C atom and L is Ci-ealkylene or a Ci-4alkoxylene.
  • X is -(CH 2 )- or -O- and Y is a 5 membered heteroarylene comprising at least one nitrogen atom.
  • X is -(CH 2 )- and Y is a 5 membered heteroarylene comprising at least one nitrogen atom.
  • X is -(CH 2 )-
  • Y is a 5 membered heteroarylene comprising at least one nitrogen atom
  • L is Ci-salkylene.
  • X is -O- and Y is a 5 membered heteroarylene comprising at least one nitrogen atom.
  • X is -(CH 2 )- and Y is selected from the group consisting of pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, thiadiazole, triazole.
  • X is -(CH 2 )-
  • Y is selected from the group consisting of pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, thiadiazole, triazole and L is Ci- salkylene.
  • X is -O- and Y is selected from the group consisting of pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, thiadiazole, triazole.
  • X is -(CH2)- and Y is isoxazole or triazole.
  • X is -(CH2)- ,Y is isoxazole or triazole and L is C1-8alkylene.
  • X is -(CH2)- and Y is triazole.
  • X is -(CH2)-, Y is triazole and L is C1-8alkylene.
  • X is -(CH 2 )-, Y is triazole and L is C 1-6 alkylene.
  • X is -O- and Y is isoxazole or triazole.
  • X is -O- and Y is isoxazole.
  • X is -O- and Y is triazole.
  • X is -(CH 2 )- and Y is selected from the group consisting of: , , , , , , , .
  • Y is selected from the group consisting of: , , , , , , .
  • X is -(CH 2 )-
  • Y is selected from the group consisting of: , , , , , , , and L is C1-8alkylene.
  • X is -O- and Y is selected from the group consisting of:
  • X is -(CH2)- and Y is selected from the group consisting of:
  • X is -(CH2)- and Y is selected from the group consisting of: and L is Ci-salkylene.
  • X is -O- and Y is selected from the group consisting of:
  • X is -(CH2)- and Y is a 5 membered heteroarylene or -C(O)(NR 12 )-, wherein said 5 membered heteroarylene comprises at least one nitrogen atom and wherein said - C(O)(NR 12 )- is linked to X via the C atom, or X is -O- and Y is a 5 membered heteroarylene comprising at least one nitrogen atom.
  • X is -(CH2)- and Y is a 5 membered heteroarylene comprising at least one nitrogen atom or -C(O)(NR 12 )-, wherein said -C(O)(NR 12 )- is linked to X via the C atom.
  • X is -(CH2)-
  • Y is a 5 membered heteroarylene comprising at least one nitrogen atom or -C(O)(NR 12 )-, wherein said -C(O)(NR 12 )- is linked to X via the C atom and L is Cisalkylene.
  • X is -(CH2)- and Y is selected from the group consisting of pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, thiadiazole, triazole and - C(O)(NR 12 )-, or X is -O- and Y is selected from the group consisting of pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, thiadiazole, triazole, wherein said -C(O)(NR 12 )- is linked to X via the C atom.
  • X is -(CH2)- and Y is selected from the group consisting of pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, thiadiazole, triazole and - C(O)(NR 12 )-, wherein said -C(O)(NR 12 )- is linked to X via the C atom.
  • X is -(CH2)- and Y is triazole or -C(O)(NR 12 )-, or X is -O- and Y is triazole or isoxazole, wherein said -C(O)(NR 12 )- is linked to X via the C atom.
  • X is -(CH2)- and Y is triazole or -C(O)(NR 12 )-, wherein said -C(O)(NR 12 )- is linked to X via the C atom.
  • X is -(CH2)-
  • Y is triazole or -C(O)(NR 12 )-, wherein said -C(O)(NR 12 )- is linked to X via the C atom and L is Ci-salkylene.
  • R9 is iso-propyl or tert-butyl.
  • R9 is iso-propyl.
  • R9 is iso-propyl and Y is a 5 membered heteroarylene comprising at least one nitrogen atom.
  • R9 is iso-propyl and Y is selected from the group consisting of pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, thiadiazole, triazole and - C(O)(NR12)-, wherein said -C(O)(NR12)- is linked to X via the C atom, preferably wherein R12 is hydrogen.
  • R9 is iso-propyl and Y is isoxazole or triazole.
  • R9 is iso-propyl and Y is selected from the group consisting of:
  • R 9 is /so-propyl and Y is selected from the group consisting of:
  • R 9 is tert-butyl.
  • R 9 is tert-butyl and Y is -C(O)(NR 12 )-, wherein said -C(O)(NR 12 )- is linked to X via the C atom.
  • R 9 is tert-butyl and Y is -C(O)(NH)-, wherein said -C(O)(NH)- is linked to X via the C atom.
  • R 9 is /so-propyl and the carbon atom to which R 9 is attached is in the (S) configuration.
  • R 9 is /so-propyl and the carbon atom to which R 9 is attached is in the (R) configuration.
  • R10 is selected from the group consisting of hydrogen, C1-6alkyl, and -C(O)OR12, wherein said C1-6alkyl is optionally substituted by -OH or -OP(O)(OH)2.
  • R10 is hydrogen.
  • R10 is selected from the group consisting of C 12 1-6alkyl, and -C(O)OR , wherein said C1-6alkyl is optionally substituted by -OH or -OP(O)(OH)2.
  • R10 is selected from the group consisting of hydrogen, C1-4alkyl, and -C(O)OR12, wherein said C1-4alkyl is optionally substituted by -OH or -OP(O)(OH)2.
  • R10 is selected from the group consisting of hydrogen, C 1-4 alkyl, and -C(O)OR12, wherein said C 1-4 alkyl is optionally substituted by -OH.
  • R10 is not hydrogen and the carbon atom to which R10 is attached is in the (S) configuration.
  • R10 is not hydrogen and the carbon atom to which R10 is attached is in the (R) configuration.
  • R10 is selected from the group consisting of hydrogen, methyl, -CH 2 OH
  • R12 is hydrogen or methyl.
  • R12 is hydrogen.
  • R12 is methyl.
  • R6 When R6 is ortho- to R7, it is labelled as R6b.
  • R6a and R6b are each independently selected from the group consisting of: hydrogen, halogen and C 6a 6b 1-3alkyl. It is to be understood that when q is 1, one of R or R is hydrogen.
  • q is 2.
  • q there are two R6’s.
  • the R6 that is meta- to R7 is labelled as R6a.
  • the R6 that is ortho- to R7 is labelled as R6b.
  • R6a and R6b are each independently halogen or C1-3alkyl.
  • q is 0 or 1.
  • R6a is hydrogen or halogen.
  • R6a is hydrogen or fluorine.
  • R6a is hydrogen.
  • R6a is fluorine.
  • R6b is selected from the group consisting of hydrogen, fluorine, chlorine and methyl.
  • R6a is hydrogen or halogen and R6b is hydrogen, halogen or C 1-3 alkyl.
  • R6a is hydrogen and R6b is hydrogen, halogen and C 1-3 alkyl.
  • R6a and R6b are each independently selected from the group consisting of hydrogen, fluorine, chlorine and methyl.
  • R6a is hydrogen or fluorine and R6b is selected from the group consisting of hydrogen, fluorine, chlorine and methyl.
  • R6a is hydrogen and R6b is selected from the group consisting of fluorine, chlorine and methyl.
  • R6a and R6b are hydrogen.
  • R7 is selected from the group consisting of: chlorine, bromine, iso- propyl, -CN, thiazole, triazole and imidazole, wherein said thiazole, triazole or imidazole is optionally substituted with R8.
  • R7 is selected from the group consisting of: halogen, C1-3alkyl, -CN, thiazole, triazole and imidazole, wherein said thiazole is substituted with R8.
  • R 7 is selected from the group consisting of: halogen, Ci-3alkyl, -CN, thiazole, triazole and imidazole, wherein said thiazole is substituted with methyl or -CH 2 OH.
  • R 7 is selected from the group consisting of: chlorine, bromine, /so- propyl, -CN, thiazole, triazole and imidazole, wherein said thiazole is substituted with methyl or -CH 2 OH.
  • R 7 is selected from the group consisting of: chlorine, bromine, iso- propyl, -CN,
  • R 8 is methyl or -CH 2 OH.
  • R 8 is methyl.
  • Preferred embodiments of compound of formula (I) are represented by compounds of formulas 1-1 to I-48, as defined hereinbelow, including any stereoisomer thereof.
  • the present invention further relates to hydrates, solvates, polymorphs, metabolites, derivatives, stereoisomers and prodrugs of a compound of formula (I), (I*), (I**), (I***), (I****), (la), (lb), (Ic), (Id), (le), (If), (Ig), or (Ih), (including all aspects and preferred embodiments thereof).
  • the present invention further relates to a pharmaceutically acceptable salt of a compound of formula (I), (I*), (I**), (I***), (I****), (la), (lb), (Ic), (Id), (le), (If), (Ig), or (Ih), (including all aspects and preferred embodiments thereof).
  • R1a and R1b are both independently selected from the group consisting of hydrogen, C1-4alkyl, C1-4haloalkyl, C1-4alkoxy, C1-4haloalkoxy, halogen, -NH2, -NH(C1-4alkyl), -N(C1-4alkyl)2, C3-5cycloalkyl and 3-5 membered heterocycloalkyl;
  • R2a and R2b are both independently selected from the group consisting of hydrogen, C1-4alkyl, C1-4haloalkyl, C1-4alkoxy, C1-4haloalkoxy, halogen, -NH2, -NH(C1-4alkyl), -N(C1-4alkyl)2, C3-5cycloalkyl and 3-5 membered heterocycloalkyl; and/or, optionally, one of R1a or R1b and one of R2a or R2b together with the carbon atoms they are attached to form
  • the compound or salt of formula (II) is of formula (II*): , wherein R1a, R1b, R2a, R2b, Z, R4, ring A, R5, m, U, V, W, p, L, q, R6 and R7 are as herein defined.
  • the compound or salt of formula (II) is of formula (II**): , wherein R1a, R1b, R2a, R2b, Z, R4, ring A, R5, m, U, V, W, p, L, q, R6 and R7 are as herein defined.
  • the compound or salt of formula (II) is of formula (II***): wherein R 1a , R 1b , R 2a , R 2b , Z, R 4 , ring A, R 5 , m, U, V, W, p, L, q, R 6 and R 7 are as herein defined.
  • the compound of formula (II) is of formula (II****): wherein R 1a , R 1b , R 2a , R 2b , Z, R 4 , ring A, R 5 , m, U, V, W, p, L, q, R 6 and R 7 are as herein defined.
  • the compound of formula (II) is of formula (Ila): wherein R 1a , R 1b , R 2a , R 2b , Z, R 4 , U, V, W, p, L, q, R 6 and R 7 are as herein defined.
  • the compound of formula (II) is of formula (lib): wherein R 1a , R 1b , R 2a , R 2b , Z, R 4 , U, V, W, p, L, q, R 6 and R 7 are as herein defined.
  • the compound of formula (II) is of formula (lib): wherein R 1a , R 1b , R 2a , R 2b , Z, R 4 , U, V, W, p, L, q, R 6 and R 7 are as herein defined.
  • R 1a , R 1b , R 2a , R 2b , Z, R 4 , U, V, W, p, L, q, R 6 and R 7 are as herein defined.
  • the compound of formula (II) is of formula (He): wherein R 1a , R 1b , R 2a , R 2b , Z, R 4 , U, V, W, p, L, q, R 6 and R 7 are as herein defined.
  • it is of formula (ll*c): wherein R 1a , R 1b , R 2a , R 2b , Z, R 4 , U, V, W, p, L, q, R 6 and R 7 are as herein defined.
  • the compound of formula (II) is of formula (lid): wherein R 1a , R 1b , R 2a , R 2b , Z, R 4 , U, V, W, p, L, q, R 6 and R 7 are as herein defined.
  • the compound of formula (II) is of formula (He): wherein R 1a , R 1b , R 2a , R 2b , Z, R 4 , U, V, W, p, L, q, R 6 and R 7 are as herein defined.
  • the compound of formula (II) is of formula (He): wherein R 1a , R 1b , R 2a , R 2b , Z, R 4 , U, V, W, p, L, q, R 6 and R 7 are as herein defined.
  • Formulas (II*), (II**), (II***), (II****), (IIa), (II*a), (IIb), (II*b), (IIc), (II*c), (IId), (II*d), (IIe), (II*e), and (IIf) can be referred to as “subformulas” of formula (II).
  • R1a or R1b is hydrogen.
  • R1a and R1b are hydrogen.
  • R2a and R2b are hydrogen.
  • R1a, R1b, R2a, R2b are hydrogen.
  • R3a and R3b are hydrogen.
  • R1a, R1b, R2a and R2b are hydrogen and Z is -CH2-.
  • R4 is selected from the group consisting of hydrogen, C1-3alkyl, C1-3haloalkyl, C1-3alkoxy, C1-3haloalkoxy, cyano-C1-3alkyl, halogen, -OH, -NH2, -NH(C1-3alkyl), -N(C1-3alkyl)2, -CN, C3-4cycloalkyl and 3-4 membered heterocycloalkyl.
  • R4 is C1-6alkyl.
  • R4 is C1-3alkyl.
  • R4 is methyl.
  • R1a, R1b, R2a and R2b are hydrogen, Z is - CH 2 - and R4 is methyl.
  • R1a, R1b, R2a and R2b are hydrogen, Z is - CH 2 -, R4 is methyl and the carbon atom to which R4 and ring A are attached is in the (S) configuration.
  • ring A is selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, oxadiazole and thiadiazole.
  • ring A is selected from the group consisting of isoxazole, isothiazole and oxadiazole.
  • ring A is selected from the group consisting of: , , , , , , .
  • A is selected from the group consisting of:
  • oxadiaziole is selected from the group consisting of
  • isoxazole isoxazole
  • L is selected from the group consisting of C 1-6 alkylene, C 2-6 alkenylene and C 1-6 alkoxylene.
  • said C 1-6 alkylene, C 2- 6 alkenylene and C 1-6 alkoxylene are linear.
  • L is selected from the group consisting of a bond, C 1-4 alkylene, C 2-4 alkenylene and C 1-4 alkoxylene.
  • said C 1-4 alkylene, C 2- 4 alkenylene and C 1-4 alkoxylene are linear.
  • L is selected from the group consisting of C 1-4 alkylene, C 2-4 alkenylene and C 1-4 alkoxylene.
  • L is selected from the group consisting of: C1-5alkylene, C3alkenylene and C3-4alkoxylene.
  • L is selected from the group consisting of: It is to be understood that “(N)” and “(C)” indicate the atom of formula (I) to which L is attached.
  • each R6, if present, is independently at each occurrence halogen or C 1-3 alkyl.
  • R6 may be meta- or ortho- to R7.
  • R6a When R6 is meta- to R7, it is labelled as R6a.
  • R6b When R6 is ortho- to R7, it is labelled as R6b.
  • R6a and R6b are each independently selected from the group consisting of: hydrogen, halogen and C 1-3 alkyl. It is to be understood that when q is 1, one of R6a or R6b is hydrogen.
  • R6a and R6b are each independently halogen or C1-3alkyl.
  • the compound of formula (II) is of formula (IIf): , wherein R1a, R1b, R2a, R2b, Z, R4, ring A, R5, m, U, V, W, p, L, and R7 are as herein defined; R6a and R6b are each independently selected from the group consisting of hydrogen, halogen and C1-3alkyl.
  • R6a is hydrogen or halogen.
  • R6a is hydrogen or fluorine.
  • R6a is hydrogen.
  • R6a is fluorine.
  • R6b is selected from the group consisting of hydrogen, fluorine, chlorine and methyl.
  • R6a is hydrogen or halogen and R1b is hydrogen, halogen or C1-3alkyl.
  • R6a is hydrogen and R6b is hydrogen, halogen and C 1-3 alkyl.
  • R6a and R6b are each independently selected from the group consisting of hydrogen, fluorine, chlorine and methyl.
  • R6a is hydrogen or fluorine and R6b is selected from the group consisting of hydrogen, fluorine, chlorine and methyl.
  • R6a is hydrogen and R6b is selected from the group consisting of fluorine, chlorine and methyl.
  • R1a and R1b are hydrogen.
  • R7 is selected from the group consisting of: chlorine, bromine, iso-propyl, -CN, thiazole, triazole and imidazole, wherein said thiazole, triazole or imidazole is optionally substituted with R8.
  • R7 is selected from the group consisting of: halogen, C1-3alkyl, -CN, thiazole, triazole and imidazole, wherein said thiazole is substituted with R8.
  • R7 is selected from the group consisting of: halogen, C1-3alkyl, -CN, thiazole, triazole and imidazole, wherein said thiazole is substituted with methyl or -CH2OH.
  • R7 is selected from the group consisting of: chlorine, bromine, iso-propyl, -CN, thiazole, triazole and imidazole, wherein said thiazole is substituted with methyl or -CH 2 OH.
  • R7 is selected from the group consisting of: chlorine, bromine, iso-propyl, -CN, , , and .
  • R8 is methyl or -CH2OH.
  • the present invention further relates to hydrates, solvates, polymorphs, metabolites, derivatives, stereoisomers and prodrugs of a compound of formula (II), (II*), (II**), (II***), (II****), (IIa), (II*a), (IIb), (II*b), (IIc), (II*c), (IId), (II*d), (IIe), (II*e), or (IIf), (including all aspects and preferred embodiments thereof).
  • the present invention further relates to a hydrate of a compound of formula (II), (II*), (II**), (II***), (II****), (IIa), (II*a), (IIb), (II*b), (IIc), (II*c), (IId), (II*d), (IIe), (II*e), or (IIf), (including all aspects and preferred embodiments thereof).
  • the present invention further relates to a solvate of a compound of formula (II), (II*), (II**), (II***), (II****), (IIa), (II*a), (IIb), (II*b), (IIc), (II*c), (IId), (II*d), (IIe), (II*e), or (IIf), (including all aspects and preferred embodiments thereof).
  • the present invention further relates to a pharmaceutically acceptable salt of a compound of formula (II), (II*), (II**), (II***), (II****), (IIa), (II*a), (IIb), (II*b), (IIc), (II*c), (IId), (II*d), (IIe), (II*e), or (IIf) (including all aspects and preferred embodiments thereof).
  • the present invention is directed to compounds inhibiting or degrading KRAS, preferably KRAS mutated at residue 12, such as KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12A and KRAS G12R inhibitors, preferably inhibitors of KRAS G12C and/or KRAS G12D, or inhibitors selective for KRAS G12D, as well as compounds inhibiting KRAS wildtype, preferably amplified, KRAS mutated at residue 13, such as KRAS G13D, or KRAS mutated at residue 61 , such as KRAS Q61 H.
  • compounds of the invention can be useful in the treatment and/or prevention of diseases and/or conditions dependent on or mediated by KRAS, preferably by KRAS mutated at residue 12, e.g. KRAS G12C, KRAS G12D, KRAS G12V, more preferably G12D, or by an amplification of KRAS wildtype, or by KRAS mutated at residue 13, e.g. KRAS G13D, or by KRAS mutated at residue 61 , such as KRAS Q61 H.
  • KRAS mutated at residue 12 e.g. KRAS G12C, KRAS G12D, KRAS G12V, more preferably G12D, or by an amplification of KRAS wildtype, or by KRAS mutated at residue 13, e.g. KRAS G13D, or by KRAS mutated at residue 61 , such as KRAS Q61 H.
  • the invention relates to a compound of the invention - or
  • the invention relates to a compound of the invention - or a pharmaceutically acceptable salt thereof - for use in a method of treatment of the human or animal body.
  • the invention relates to a compound of the invention - or a pharmaceutically acceptable salt thereof - for use in the treatment and/or prevention of a disease and/or condition mediated by KRAS, preferably by KRAS mutated at residue 12, e.g. KRAS G12C, KRAS G12D, KRAS G12V, more preferably G12D, or by an amplification of KRAS wildtype, or by KRAS mutated at residue 13, e.g. KRAS G13D.
  • the invention relates to the use of a compound of the invention - or a pharmaceutically acceptable salt thereof - in the manufacture of a medicament for the treatment and/or prevention of a disease and/or condition mediated by KRAS, preferably by KRAS mutated at residue 12, e.g. KRAS G12C, KRAS G12D, KRAS G12V, more preferably G12D, or by an amplification of KRAS wildtype, or by KRAS mutated at residue 13, e.g. KRAS G13D.
  • the invention relates to a method for the treatment and/or prevention of a disease and/or condition mediated by KRAS, preferably by KRAS mutated at residue 12, e.g. KRAS G12C, KRAS G12D, KRAS G12V, more preferably G12D, or by an amplification of KRAS wildtype, or by KRAS mutated at residue 13, e.g. KRAS G13D, comprising administering a therapeutically effective amount of a compound of the invention - or a pharmaceutically acceptable salt thereof - to a human being.
  • the invention relates to a compound of the invention - or a pharmaceutically acceptable salt thereof - for use in the treatment and/or prevention of cancer.
  • the invention relates to a compound of the invention - or a pharmaceutically acceptable salt thereof - for use in a method of treatment and/or prevention of cancer in the human or animal body.
  • the invention relates to the use of a compound of the invention - or a pharmaceutically acceptable salt thereof - in the manufacture of a medicament for the treatment and/or prevention of cancer.
  • the invention relates to a method for the treatment and/or prevention of cancer comprising administering a therapeutically effective amount of a compound of the invention - or a pharmaceutically acceptable salt thereof - to a human being.
  • the cancer as defined herein comprises a KRAS mutation.
  • KRAS mutations include e.g. mutations of the KRAS gene and of the KRAS protein, such as overexpressed KRAS, amplified KRAS or KRAS, KRAS mutated at residue 12, KRAS mutated at residue 13, KRAS mutated at residue 61 , KRAS mutated at residue 146, in particular KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12S, KRAS G13C, KRAS G13D, KRAS G13V, KRAS Q61H, KRAS Q61E, KRAS Q61P, KRAS A146P, KRAS A146T, KRAS A146V.
  • KRAS may present one or more of these mutations/alterations.
  • the cancer as defined herein comprises a BRAF mutation in addition or in alternative to the KRAS mutation.
  • Said BRAF mutation is in particular a class III BRAF mutation, e.g. as defined in Z. Yao, Nature, 2017, 548, 234-238.
  • the cancer as defined herein comprises a mutation in a receptor tyrosine kinase (RTK), including EGFR, MET and ERBB2 mutations, in addition or in alternative to the KRAS mutation.
  • RTK receptor tyrosine kinase
  • the invention relates to a compound of the invention - or a pharmaceutically acceptable salt thereof - for use in the treatment and/or prevention of cancer, wherein the cancer comprises a KRAS mutation, said KRAS mutation being preferably selected from the group consisting of: KRAS G12C, KRAS G12D, KRAS G12V, KRAS G13D; or an amplification of KRAS wildtype, amplification of the KRAS gene or overexpression of KRAS.
  • the invention relates to the use of a compound of the invention - or a pharmaceutically acceptable salt thereof - in the manufacture of a medicament for the treatment and/or prevention of cancer, wherein the cancer comprises a KRAS mutation, said KRAS mutation being preferably selected from the group consisting of: KRAS G12C, KRAS G12D, KRAS G12V, KRAS G13D; or an amplification of KRAS wildtype, amplification of the KRAS gene or overexpression of KRAS.
  • the invention relates to a method for the treatment and/or prevention of cancer comprising administering a therapeutically effective amount of a compound of the invention - or a pharmaceutically acceptable salt thereof - to a human being, wherein the cancer comprises a KRAS mutation, said KRAS mutation being preferably selected from the group consisting of: KRAS G12C, KRAS G12D, KRAS G12V, KRAS G13D; or an amplification of KRAS wildtype, amplification of the KRAS gene or overexpression of KRAS.
  • the invention relates to a compound of the invention - or a pharmaceutically acceptable salt thereof - for use in the treatment and/or prevention of cancer, wherein the cancer comprises a KRAS G12D mutation.
  • the invention relates to a compound of the invention - or a pharmaceutically acceptable salt thereof - for use in the treatment and/or prevention of cancer, wherein the cancer comprises a KRAS G12V mutation.
  • the invention relates to a compound of the invention - or a pharmaceutically acceptable salt thereof - for use in the treatment and/or prevention of cancer, wherein the cancer comprises a KRAS G13D mutation.
  • the invention relates to a compound of the invention - or a pharmaceutically acceptable salt thereof - for use in the treatment and/or prevention of cancer, wherein the cancer comprises wildtype amplified KRAS.
  • the invention relates to a compound of the invention - or a pharmaceutically acceptable salt thereof - for use in a method of inhibiting or degrading KRAS, wherein KRAS can be wild-type, mutated or amplified as defined herein.
  • the invention relates to the use of a compound of the invention - or a pharmaceutically acceptable salt thereof - in the manufacture of a medicament for use in a method of inhibiting or degrading KRAS, wherein KRAS can be wild-type, amplified or mutated as herein defined.
  • the invention relates to a method for inhibiting or degrading KRAS, wherein KRAS can be wild-type, amplified or mutated as herein defined, comprising administering a therapeutically effective amount of a compound of the invention - or a pharmaceutically acceptable salt thereof - to a human being.
  • the invention relates to a compound the invention - or a pharmaceutically acceptable salt thereof - for use in a method of degrading or inducing degradation of KRAS, wherein KRAS can be wild-type, amplified or mutated as herein defined above.
  • the invention relates to the use of a compound of the invention - or a pharmaceutically acceptable salt thereof - in the manufacture of a medicament for use in a method of degrading or inducing degradation of KRAS, wherein KRAS can be wild-type, amplified or mutated as herein defined.
  • the invention relates to a method for degrading or inducing degradation of KRAS, wherein KRAS can be wild-type, amplified or mutated as herein defined, comprising administering a therapeutically effective amount of a compound of the invention - or a pharmaceutically acceptable salt thereof - to a human being.
  • Another aspect is based on identifying a link between the KRAS status of a patient and potential susceptibility to treatment with a compound of the invention - or a pharmaceutically acceptable salt thereof.
  • a KRAS inhibitor or degrader such as a compound of the invention - or a pharmaceutically acceptable salt thereof - may then advantageously be used to treat patients with a disease dependent on KRAS, who may be resistant to other therapies. This therefore provides opportunities, methods and tools for selecting patients for treatment with a compound of the invention, particularly cancer patients.
  • the selection is based on whether the tumor cells to be treated possess wild-type, preferably amplified, or KRAS mutated at residue 12, preferably G12C, G12D or G12V gene, or KRAS mutated at residue 13, preferably G13D gene.
  • the KRAS gene status could therefore be used as a biomarker to indicate that selecting treatment with a compound of the invention may be advantageous.
  • a method for selecting a patient for treatment with a compound of the invention - or a pharmaceutically acceptable salt thereof comprising
  • KRAS gene in the patient's tumor cell-containing sample encodes for wild-type (glycine at position 12) or mutant (cysteine, aspartic acid, valine, alanine or aginine at position 12, aspartic acid at position 13, amplification and/or overexpression) KRAS protein;
  • the method may include or exclude the actual patient sample isolation step.
  • the patient is selected for treatment with a compound of the invention - or a pharmaceutically acceptable salt thereof - if the tumor cell DNA has a mutant KRAS gene.
  • a compound of the invention - or a pharmaceutically acceptable salt thereof - for use in treating a cancer with tumor cells harbouring a KRAS mutation or an amplification of KRAS wildtype.
  • a compound of the invention - or a pharmaceutically acceptable salt thereof - for use in treating a cancer with tumor cells harbouring a G12C mutant, G12D mutant, G12V mutant or G13D mutant KRAS gene or an amplification of KRAS wildtype.
  • a compound of the invention - or a pharmaceutically acceptable salt thereof - for use in treating a cancer with tumor cells harbouring a G12D mutant KRAS gene.
  • a compound of the invention - or a pharmaceutically acceptable salt thereof - for use in treating a cancer with tumor cells harbouring a G12V mutant KRAS gene.
  • a compound of the invention - or a pharmaceutically acceptable salt thereof - for use in treating a cancer with tumor cells harbouring a G13D mutant KRAS gene.
  • a compound of the invention - or a pharmaceutically acceptable salt thereof - for use in treating a cancer with tumor cells harbouring wildtype amplified KRAS or overexpressed KRAS.
  • a method of treating a cancer with tumor cells harbouring a G12C mutant, G12D mutant, G12V mutant, G12A mutant, G13D mutant or G12R mutant KRAS gene or an amplification of KRAS wildtype gene comprising administering an effective amount of a compound of the invention - or a pharmaceutically acceptable salt thereof - to a human being.
  • a method of treating a cancer with tumor cells harbouring a G12C mutant, G12D mutant, G12V mutant, G12A mutant, G13D mutant or G12R mutant KRAS gene or an amplification of KRAS wildtype gene comprising administering an effective amount of a compound of the invention - or a pharmaceutically acceptable salt thereof.
  • Determining whether a tumor or cancer comprises a KRAS mutation can be undertaken by assessing the nucleotide sequence encoding the KRAS protein, by assessing the amino acid sequence of the KRAS protein, or by assessing the characteristics of a putative KRAS mutant protein.
  • the sequence of wild-type human KRAS is known in the art. Methods for detecting a mutation in a KRAS nucleotide sequence are known by those of skill in the art.
  • PCR-RFLP polymerase chain reaction-restriction fragment length polymorphism
  • PCR-SSCP polymerase chain reaction-single strand conformation polymorphism
  • MASA mutant allele-specific PCR amplification
  • direct sequencing primer extension reactions
  • electrophoresis oligonucleotide ligation assays
  • hybridization assays TaqMan assays
  • SNP genotyping assays high resolution melting assays and microarray analyses.
  • samples are evaluated for KRAS mutations by real-time PCR.
  • fluorescent probes specific for the KRAS mutation can be used. When a mutation is present, the probe binds and fluorescence is detected.
  • the KRAS mutation is identified using a direct sequencing method of specific regions (e.g. exon 2 and/or exon 3) in the KRAS gene. This technique will identify all possible mutations in the region sequenced. Methods for detecting a mutation in a KRAS, protein are known by those of skill in the art and may not only be applied to identify presence of mutated/altered KRAS at baseline but also to monitor response to treatment in particular treatment related depletion of WT or mutated KRAS from tumor samples.
  • a binding agent e.g. an antibody
  • protein electrophoresis e.g. an antibody
  • Western blotting e.g. an antibody to detect wild type or mutated KRAS by mass spectrometry-based approaches.
  • Methods for determining whether a tumor or cancer comprises a KRAS mutation can use a variety of samples.
  • the sample is taken from a subject having a tumor or cancer.
  • the sample is a fresh tumor/cancer sample.
  • the sample is a frozen tumor/cancer sample.
  • the sample is a formalin-fixed paraffin-embedded sample.
  • the sample is processed to a cell lysate.
  • the sample is processed to DNA or RNA.
  • the sample is a liquid biopsy and the test is done on a sample of blood to look for cancer cells from a tumor that are circulating in the blood or for pieces of DNA from tumor cells that are in the blood.
  • the disease/condition/cancer/tumors/cancer cells to be treated/prevented with a compound of the invention - or a pharmaceutically acceptable salt thereof - is selected from the group consisting of pancreatic cancer, lung cancer, colorectal cancer, cholangiocarcinoma, appendiceal cancer, multiple myeloma, melanoma, uterine cancer, endometrial cancer, thyroid cancer, acute myeloid leukaemia, bladder cancer, urothelial cancer, gastric cancer, esophageal cancer, gastroesophageal cancer, cervical cancer, head and neck squamous cell carcinoma, diffuse large B cell lymphoma, chronic lymphocytic leukaemia, hepatocellular cancer, breast cancer, ovarian cancer, prostate cancer, glioblastoma, renal cancer and sarcomas.
  • the disease/condition/cancer/tumors/cancer cells to be treated/prevented with a compound of the invention - or a pharmaceutically acceptable salt thereof - is selected from the group consisting of: pancreatic cancer, lung cancer, ovarian cancer, colorectal cancer (CRC), gastric cancer, gastroesophageal junction cancer (GEJC) and esophageal cancer.
  • a compound of the invention - or a pharmaceutically acceptable salt thereof is selected from the group consisting of: pancreatic cancer, lung cancer, ovarian cancer, colorectal cancer (CRC), gastric cancer, gastroesophageal junction cancer (GEJC) and esophageal cancer.
  • pancreatic cancer preferably pancreatic ductal adenocarcinoma (PDAC)
  • lung cancer preferably non-small cell lung cancer (NSCLC)
  • gastric cancer cholangiocarcinoma
  • colorectal cancer preferably colorectal adenocarcinoma
  • said pancreatic cancer, lung cancer, cholangiocarcinoma, colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) or colorectal adenocarcinoma comprises a KRAS mutation, in particular a KRAS G12D or KRAS G12V mutation.
  • said non-small cell lung cancer (NSCLC) comprises a mutation (in particular a loss-of-function mutation) in the NF1 gene.
  • gastric cancer, ovarian cancer or esophageal cancer gastric cancer, ovarian cancer or esophageal cancer
  • said gastric cancer or esophageal cancer being preferably selected from the group consisting of: gastric adenocarcinoma (GAC), esophageal adenocarcinoma (EAC) and gastroesophageal junction cancer (GEJC).
  • said gastric cancer, ovarian cancer, esophageal cancer, gastric adenocarcinoma (GAC), esophageal adenocarcinoma (EAC) or gastroesophageal junction cancer (GEJC) comprises a KRAS mutation or wildtype amplified KRAS.
  • the cancer to be treated/prevented with a compound of the invention - or a pharmaceutically acceptable salt thereof - according to the methods and uses as herein (above and below) defined and disclosed is selected from the group consisting of:
  • lung adenocarcinoma preferably non-small cell lung cancer (NSCLC) harboring at least one KRAS mutation, in particular KRAS wild type amplification;
  • NSCLC non-small cell lung cancer
  • pancreatic adenocarcinoma preferably pancreatic ductal adenocarcinoma (PDAC) harboring at least one KRAS mutation, in particular KRAS wild type amplification;
  • PDAC pancreatic ductal adenocarcinoma
  • gastroesophageal junction cancer harboring at least one KRAS mutation, in particular KRAS wild type amplification.
  • cancer as used herein (above or below) includes drug-resistant cancer and cancer that has failed one, two or more lines of mono- or combination therapy with one or more anti-cancer agents.
  • cancer (and any embodiment thereof) refers to any cancer (especially the cancer species defined hereinabove and hereinbelow) that is resistant to treatment with a KRAS G12C inhibitor.
  • a RASopathy preferably selected from the group consisting of Neurofibromatosis type 1 (NF1), Noonan Syndrome (NS), Noonan Syndrome with Multiple Lentigines (NSML) (also referred to as LEOPARD syndrome), Capillary Malformation-Arteriovenous Malformation Syndrome (CM-AVM), Costello Syndrome (CS), Cardio-Facio-Cutaneous Syndrome (CFC), Legius Syndrome (also known as NF1-like Syndrome) and Hereditary gingival fibromatosis.
  • NF1 Neurofibromatosis type 1
  • NS Noonan Syndrome
  • NSML Noonan Syndrome with Multiple Lentigines
  • LEOPARD syndrome also referred to as LEOPARD syndrome
  • CM-AVM Capillary Malformation-Arteriovenous Malformation Syndrome
  • CS Costello Syndrome
  • CFC Cardio-Facio-Cutaneous Syndrome
  • Legius Syndrome also known as NF1-like Syndrome
  • Hereditary gingival fibromatosis preferably selected from the group consisting
  • cancers, tumors and other proliferative diseases may be treated with compounds of the invention - or a pharmaceutically acceptable salt thereof - without being restricted thereto.
  • the methods of treatment, methods, uses, compounds for use and pharmaceutical compositions for use as disclosed herein are applied in treatments of diseases/conditions/cancers/tumors which (/.e.
  • KRAS mutation including at position 12 (preferably a G12C, G12D, G12V, G12A, G12R mutation) or an amplification of KRAS wild-type) alternatively they have been identified to harbour a KRAS mutation at position 12 (preferably a G12C, G12D, G12V, G12A, G12R mutation) as herein described and/or referred or an amplification of KRAS wildtype: cancers/tumors/carcinomas of the head and neck: e.g.
  • tumors/carcinomas/cancers of the nasal cavity paranasal sinuses, nasopharynx, oral cavity (including lip, gum, alveolar ridge, retromolar trigone, floor of mouth, tongue, hard palate, buccal mucosa), oropharynx (including base of tongue, tonsil, tonsillar pilar, soft palate, tonsillar fossa, pharyngeal wall), middle ear, larynx (including supraglottis, glottis, subglottis, vocal cords), hypopharynx, salivary glands (including minor salivary glands); cancers/tumors/carcinomas of the lung: e.g.
  • non-small cell lung cancer SCCLC
  • SCLC small cell lung cancer
  • neoplasms of the mediastinum e.g.
  • neurogenic tumors including neurofibroma, neurilemoma, malignant schwannoma, neurosarcoma, ganglioneuroblastoma, ganglioneuroma, neuroblastoma, pheochromocytoma, paraganglioma), germ cell tumors (including seminoma, teratoma, non-seminoma), thymic tumors (including thymoma, thymolipoma, thymic carcinoma, thymic carcinoid), mesenchymal tumors (including fibroma, fibrosarcoma, lipoma, liposarcoma, myxoma, mesothelioma, leiomyoma, leiomyosarcoma, rhabdomyosarcoma, xanthogranuloma, mesenchymoma, hemangioma, hemangioendothelioma, hemangio
  • tumors/carcinomas/ cancers of the esophagus e.g. esophageal cancer, gastroesophageal junction cancer), stomach (gastric cancer), pancreas, liver and biliary tree (including hepatocellular carcinoma (HCC), e.g.
  • HCC hepatocellular carcinoma
  • HCC childhood HCC, fibrolamellar HCC, combined HCC, spindle cell HCC, clear cell HCC, giant cell HCC, carcinosarcoma HCC, sclerosing HCC; hepatoblastoma; cholangiocarcinoma; cholangiocellular carcinoma; hepatic cystadenocarcinoma; angiosarcoma, hemangioendothelioma, leiomyosarcoma, malignant schwannoma, fibrosarcoma, Klatskin tumor), gall bladder, extrahepatic bile ducts, small intestine (including duodenum, jejunum, ileum), large intestine (including cecum, colon, rectum, anus; colorectal cancer, gastrointestinal stroma tumor (GIST)), genitourinary system (including kidney, e.g.
  • renal pelvis renal cell carcinoma (RCC), nephroblastoma (Wilms' tumor), hypernephroma, Grawitz tumor; ureter; urinary bladder, e.g. urachal cancer, urothelial cancer; urethra, e.g. distal, bulbomembranous, prostatic; prostate (androgen dependent, androgen independent, castration resistant, hormone independent, hormone refractory), penis); cancers/tumors/carcinomas of the testis: e.g. seminomas, non-seminomas, gynecologic cancers/tumors/carcinomas: e.g.
  • cancers/tumors/carcinomas of the breast e.g. mammary carcinoma (infiltrating ductal, colloid, lobular invasive, tubular, adenocystic, papillary, medullary, mucinous), hormone receptor positive breast cancer (estrogen receptor positive breast cancer, progesterone receptor positive breast cancer), Her2 positive breast cancer, triple negative breast cancer, Paget's disease of the breast; cancers/tumors/carcinomas of the endocrine system: e.g.
  • tumors/carcinomas/cancers of the endocrine glands thyroid gland (thyroid carcinomas/tumors; papillary, follicular, anaplastic, medullary), parathyroid gland (parathyroid carcinoma/tumor), adrenal cortex (adrenal cortical carcinoma/tumors), pituitary gland (including prolactinoma, craniopharyngioma), thymus, adrenal glands, pineal gland, carotid body, islet cell tumors, paraganglion, pancreatic endocrine tumors (PET; non-functional PET, PPoma, gastrinoma, insulinoma, VIPoma, glucagonoma, somatostatinoma, GRFoma, ACTHoma), carcinoid tumors; sarcomas of the soft tissues: e.g.
  • fibrosarcoma fibrous histiocytoma, liposarcoma, leiomyosarcoma, rhabdomyosarcoma, angiosarcoma, lymphangiosarcoma, Kaposi's sarcoma, glomus tumor, hemangiopericytoma, synovial sarcoma, giant cell tumor of tendon sheath, solitary fibrous tumor of pleura and peritoneum, diffuse mesothelioma, malignant peripheral nerve sheath tumor (MPNST), granular cell tumor, clear cell sarcoma, melanocytic schwannoma, plexosarcoma, neuroblastoma, ganglioneuroblastoma, neuroepithelioma, extraskeletal Ewing's sarcoma, paraganglioma, extraskeletal chondrosarcoma, extraskeletal osteosarcoma, mesenchymoma, alveolar soft part sarcoma
  • myeloma myeloma, reticulum cell sarcoma, chondrosarcoma (including central, peripheral, clear cell, mesenchymal chondrosarcoma), osteosarcoma (including parosteal, periosteal, high-grade surface, small cell, radiation-induced osteosarcoma, Paget's sarcoma), Ewing's tumor, malignant giant cell tumor, adamantinoma, (fibrous) histiocytoma, fibrosarcoma, chordoma, small round cell sarcoma, hemangioendothelioma, hemangiopericytoma, osteochondroma, osteoid osteoma, osteoblastoma, eosinophilic granuloma, chondroblastoma; mesothelioma: e.g.
  • pleural mesothelioma peritoneal mesothelioma
  • cancers of the skin e.g. basal cell carcinoma, squamous cell carcinoma, Merkel's cell carcinoma, melanoma (including cutaneous, superficial spreading, lentigo maligna, acral lentiginous, nodular, intraocular melanoma), actinic keratosis, eyelid cancer
  • neoplasms of the central nervous system and brain e.g.
  • astrocytoma (cerebral, cerebellar, diffuse, fibrillary, anaplastic, pilocytic, protoplasmic, gemistocytary), glioblastoma, gliomas, oligodendrogliomas, oligoastrocytomas, ependymomas, ependymoblastomas, choroid plexus tumors, medulloblastomas, meningiomas, schwannomas, hemangioblastomas, hemangiomas, hemangiopericytomas, neuromas, ganglioneuromas, neuroblastomas, retinoblastomas, neurinomas (e.g.
  • B-cell non-Hodgkin lymphomas (including small lymphocytic lymphoma (SLL), lymphoplasmacytoid lymphoma (LPL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large cell lymphoma (DLCL), Burkitt's lymphoma (BL)), T-cell non-Hodgkin lymphomas (including anaplastic large cell lymphoma (ALCL), adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL), peripheral T- cell lymphoma (PTCL)), lymphoblastic T-cell lymphoma (T-LBL), adult T-cell lymphoma, lymphoblastic B-cell lymphoma (B-LBL), immunocytoma, chronic B-cell lymphocytic leukemia (B-CLL
  • NDL small lymphocytic lymphoma
  • LPL lymphoplasmacytoid lymphoma
  • All cancers/tumors/carcinomas mentioned above which are characterized by their specific location/origin in the body are meant to include both the primary tumors and the metastatic tumors derived therefrom.
  • Epithelial cancers e.g. squamous cell carcinoma (SCC) (carcinoma in situ, superficially invasive, verrucous carcinoma, pseudosarcoma, anaplastic, transitional cell, lymphoepithelial), adenocarcinoma (AC) (well-differentiated, mucinous, papillary, pleomorphic giant cell, ductal, small cell, signet-ring cell, spindle cell, clear cell, oat cell, colloid, adenosquamous, mucoepidermoid, adenoid cystic), mucinous cystadenocarcinoma, acinar cell carcinoma, large cell carcinoma, small cell carcinoma, neuroendocrine tumors (small cell carcinoma, paraganglioma, carcinoid); oncocytic carcinoma;
  • SCC squamous cell carcinoma
  • AC adenocarcinoma
  • AC well-differentiated, mucinous, papillary, pleomorphic
  • Nonepithilial cancers e.g. sarcomas (fibrosarcoma, chondrosarcoma, rhabdomyosarcoma, leiomyosarcoma, hemangiosarcoma, giant cell sarcoma, lymphosarcoma, fibrous histiocytoma, liposarcoma, angiosarcoma, lymphangiosarcoma, neurofibrosarcoma), lymphoma, melanoma, germ cell tumors, hematological neoplasms, mixed and undifferentiated carcinomas;
  • sarcomas fibrosarcoma, chondrosarcoma, rhabdomyosarcoma, leiomyosarcoma, hemangiosarcoma, giant cell sarcoma, lymphosarcoma, fibrous histiocytoma, liposarcoma, angiosarcoma, lymphangiosarcoma, neurofibros
  • the compounds of the invention may be used in therapeutic regimens in the context of first line, second line, or any further line treatments.
  • the compounds of the invention may be used for the prevention, short-term or long-term treatment of the above-mentioned diseases/conditions/cancers/tumors, optionally also in combination with radiotherapy and/or surgery.
  • the compounds of the invention - or the pharmaceutically acceptable salts thereof - and the pharmaceutical compositions comprising such compounds or salts may also be coadministered with other pharmacologically active substances, e.g. with other anti-neoplastic compounds ⁇ e.g. chemotherapy), or used in combination with other treatments, such as radiation or surgical intervention, either as an adjuvant prior to surgery or post-operatively.
  • the pharmacologically active substance(s) for co-administration is/are (an) anti- neoplastic compound(s).
  • the invention relates to a compound of the invention - or a pharmaceutically acceptable salt thereof - for use as hereinbefore defined wherein said compound is administered before, after or together with one or more other pharmacologically active substance(s).
  • the invention relates to a compound of the invention - or a pharmaceutically acceptable salt thereof - for use as hereinbefore defined, wherein said compound is administered in combination with one or more other pharmacologically active substance(s).
  • the invention relates to the use of a compound of the invention - or a pharmaceutically acceptable salt thereof - as hereinbefore defined wherein said compound is to be administered before, after or together with one or more other pharmacologically active substance(s).
  • the invention relates to a method e.g. a method for the treatment and/or prevention) as hereinbefore defined wherein the compound of the invention - or a pharmaceutically acceptable salt thereof - is administered before, after or together with a therapeutically effective amount of one or more other pharmacologically active substance(s).
  • the invention relates to a method ⁇ e.g. a method for the treatment and/or prevention) as hereinbefore defined wherein the compound of the invention - or a pharmaceutically acceptable salt thereof - is administered in combination with a therapeutically effective amount of one or more other pharmacologically active substance(s).
  • the invention relates to a method for the treatment and/or prevention of cancer comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the invention - or a pharmaceutically acceptable salt thereof - and a therapeutically effective amount of one or more other pharmacologically active substance(s), wherein the compound of the invention - or a pharmaceutically acceptable salt thereof - is administered simultaneously, concurrently, sequentially, successively, alternately or separately with the one or more other pharmacologically active substance(s).
  • the invention relates to a method for the treatment and/or prevention of cancer comprising administering to a patient in need thereof a therapeutically effective amount of an inhibitor of a KRAS mutated at residue 12 or 13, such as KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12A, KRAS G13D and/or KRAS G12R inhibitors, preferably KRAS G12C, KRAS G12D or selective KRAS G12D inhibitors - or a pharmaceutically acceptable salt thereof - and a therapeutically effective amount of one or more other pharmacologically active substance(s), wherein the inhibitor - or a pharmaceutically acceptable salt thereof - is administered in combination with the one or more other pharmacologically active substance(s).
  • an inhibitor of a KRAS mutated at residue 12 or 13 such as KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12A, KRAS G13D and/or KRAS
  • the invention in a further aspect relates to a method for the treatment and/or prevention of cancer comprising administering to a patient in need thereof a therapeutically effective amount of a KRAS inhibitor or degrader (preferably a pan-KRAS inhibitor or degrader) and a therapeutically effective amount of one or more other pharmacologically active substance(s), wherein the KRAS inhibitor or degrader (preferably the pan-KRAS inhibitor or degrader) is administered in combination with the one or more other pharmacologically active substance(s).
  • a KRAS inhibitor or degrader preferably a pan-KRAS inhibitor or degrader
  • the KRAS inhibitor or degrader preferably the pan-KRAS inhibitor or degrader
  • the invention relates to a compound of the invention - or a pharmaceutically acceptable salt thereof - for use in the treatment and/or prevention of cancer, wherein the compound of the invention - or a pharmaceutically acceptable salt thereof - is administered simultaneously, concurrently, sequentially, successively, alternately or separately with the one or more other pharmacologically active substance(s).
  • the invention relates to a KRAS inhibitor or degrader (preferably a pan- KRAS inhibitor or degrader) for use in the treatment and/or prevention of cancer, wherein KRAS inhibitor or degrader (preferably a pan-KRAS inhibitor or degrader) is administered in combination with the one or more other pharmacologically active substance(s).
  • the invention relates to an inhibitor or degrader of KRAS wildtype amplified or overexpressed - or a pharmaceutically acceptable salt thereof - for use in the treatment and/or prevention of cancer, wherein the inhibitor or degrader - or a pharmaceutically acceptable salt thereof - is administered in combination with the one or more other pharmacologically active substance(s).
  • the invention relates to a kit comprising • a first pharmaceutical composition or dosage form comprising a compound of the invention - or a pharmaceutically acceptable salt thereof - and, optionally, one or more pharmaceutically acceptable excipient(s), and
  • a second pharmaceutical composition or dosage form comprising another pharmacologically active substance, and, optionally, one or more pharmaceutically acceptable excipient(s), for use in the treatment and/or prevention of cancer, wherein the first pharmaceutical composition is to be administered simultaneously, concurrently, sequentially, successively, alternately or separately with the second and/or additional pharmaceutical composition or dosage form.
  • kit for said use comprises a third pharmaceutical composition or dosage form comprising a third pharmaceutical composition or dosage form comprising still another pharmacologically active substance, and, optionally, one or more pharmaceutically acceptable excipient(s).
  • the components (/.e. the combination partners) of the combinations, kits, uses, methods and compounds for use according to the invention are administered simultaneously.
  • the components (/.e. the combination partners) of the combinations, kits, uses, methods and compounds for use according to the invention are administered concurrently.
  • the components (/.e. the combination partners) of the combinations, kits, uses, methods and compounds for use according to the invention are administered sequentially.
  • the components (/.e. the combination partners) of the combinations, kits, uses, methods and compounds for use according to the invention are administered successively.
  • the components (/.e. the combination partners) of the combinations, kits, uses, methods and compounds for use according to the invention are administered alternately.
  • the components (/.e. the combination partners) of the combinations, kits, uses, methods and compounds for use according to the invention are administered separately.
  • pharmacologically active substance(s) to be used together/in combination with the compound of the invention - or a pharmaceutically acceptable salt thereof - or in the medical uses, uses, methods of treatment and/or prevention, pharmaceutical compositions as herein (above and below) defined can be selected from any one or more of the following (preferably there is one or two additional pharmacologically active substance used in all these embodiments):
  • an inhibitor of EGFR and/or ErbB2 (HER2) and/or ErbB3 (HER3) and/or ErbB4 (HER4) or of any mutants thereof a. irreversible inhibitors: e.g. afatinib, dacomitinib, canertinib, neratinib, avitinib, poziotinib, AV 412, PF-6274484, HKI 357, olmutinib, osimertinib, almonertinib, Ricoartinib, lazertinib, pelitinib; b. reversible inhibitors: e.g.
  • ant/-EGFR antibodies e.g. necitumumab, panitumumab, cetuximab, amivantamab;
  • ant/-HER2 antibodies e.g. pertuzumab, trastuzumab, trastuzumab emtansine; e. inhibitors of mutant EGFR; f. an inhibitor of HER2 with exon 20 mutations; g. preferred irreversible inhibitor is afatinib; h. preferred ant/-EGFR antibody is cetuximab.
  • an inhibitor of MEK and/or of mutants thereof a. e.g. trametinib, cobimetinib, binimetinib, selumetinib, refametinib; b. preferred is trametinib c. a MEK inhibitor as disclosed in WO 2013/136249; d. a MEK inhibitor as disclosed in WO 2013/136254
  • an inhibitor of SOS1 and/or of any mutants thereof (/.e. a compound that modulates/inhibits the GEF functionality of SOS1 , e.g. by binding to SOS1 and preventing protein-protein interaction between SOS1 and a (mutant) Ras protein, e.g. KRAS) a. e.g. BAY-293; b. a SOS1 inhibitor as disclosed in WO 2018/115380; c. a SOS1 inhibitor as disclosed in WO 2019/122129; d. a SOS1 inhibitor as disclosed in WO 2020/180768, WO 2020/180770, WO 2018/172250 and WO 2019/201848.
  • an inhibitor of YAP1, WWTR1, TEAD1, TEAD2, TEAD3 and / or TEAD4 a. reversible inhibitors of TEAD transcription factors (e.g. disclosed in WO 2018/204532); b. irreversible inhibitors of TEAD transcription factors (e.g. disclosed in WO 2020/243423); c. protein-protein interaction inhibitors of the YAP/T AZ: :TEAD interaction (e.g. disclosed in WO 2021/186324); d. inhibitors of TEAD palmitoylation.
  • a RAS vaccine a. e.g. TG02 (Targovax).
  • a cell cycle inhibitor a. e.g. inhibitors of CDK4/6 and/or of any mutants therof i. e.g. palbociclib, ribociclib, abemaciclib, trilaciclib, PF-06873600; ii. preferred are palbociclib and abemaciclib; iii. most preferred is abemaciclib.
  • an inhibitor of SHP2 and/or of any mutants thereof a. e.g. SHP099, TNO155, RMC-4550, RMC-4630, IACS-13909.
  • an inhibitor of FGFR1 and/or FGFR2 and/or FGFR3 and/or of any mutants thereof a. e.g. ponatinib, infigratinib, nintedanib.
  • a taxane a. e.g. paclitaxel, nab-paclitaxel, docetaxel; b. preferred is paclitaxel.
  • a platinum-containing compound a. e.g. cisplatin, carboplatin, oxaliplatin b. preferred is oxaliplatin.
  • an immunotherapeutic agent a. e.g. an immune checkpoint inhibitor i. e.g.
  • a topoisomerase inhibitor a. e.g. irinotecan, liposomal irinotecan (nal-IRI), topotecan, etoposide; b. most preferred is irinotecan and liposomal irinotecan (nal-IRI).
  • an epigenetic regulator a. e.g. a BET inhibitor i. e.g. JQ-1, GSK 525762, OTX-015, CPI-0610, TEN-010, OTX-015, PLX51107, ABBV-075, ABBV-744, BMS986158, TGI-1601, CC-90010, AZD5153, I-BET151, BI 894999. 21.
  • an inhibitor of a kinase of the SrcB subfamily and/or of any mutants thereof i.e. an inhibitor of Lek, Hck, Blk, Lyn and/or of any mutants thereof
  • an apoptosis regulator a. e.g. an MDM2 inhibitor, e.g. an inhibitor of the interaction between p53 (preferably functional p53, most preferably wt p53) and MDM2 and/or of any mutants thereof; i. e.g. HDM-201 , NVP-CGM097, RG-7112, MK-8242, RG-7388, SAR405838, AMG-232, DS-3032, RG-7775, APG-115; ii. preferred are HDM-201 , RG-7388 and AMG-232; iii. an MDM2 inhibitor as disclosed in WO 2015/155332; iv.
  • an MDM2 inhibitor e.g. an MDM2 inhibitor, e.g. an inhibitor of the interaction between p53 (preferably functional p53, most preferably wt p53) and MDM2 and/or of any mutants thereof; i. e.g. HDM-201
  • an inhibitor of c-MET and/or of any mutants thereof a. e.g. savolitinib, cabozantinib, foretinib; b. MET antibodies, e.g. emibetuzumab, amivantamab;
  • an inhibitor of ERK and/or of any mutants thereof a. e.g. ulixertinib, LTT462;
  • an inhibitor of farnesyl transferase and/or of any mutants thereof a. e.g. tipifarnib;
  • one other pharmacologically active substance is to be administered before, after or together with the compound of the invention, wherein said one other pharmacologically active substance is
  • one other pharmacologically active substance is to be administered in combination with the compound of the invention – or a pharmaceutically acceptable salt thereof – wherein said one other pharmacologically active substance is ⁇ a SOS1 inhibitor; or ⁇ a MEK inhibitor; or ⁇ trametinib; or ⁇ an anti-PD-1 antibody; or ⁇ ezabenlimab; or ⁇ cetuximab; or ⁇ afatinib; or ⁇ standard of care (SoC) in a given indication; or ⁇ a PI3 kinase inhibitor; or ⁇ an inhibitor of TEAD palmitoylation; or ⁇ a YAP/TAZ::TEAD inhibitor.
  • SoC standard of care
  • two other pharmacologically active substances are to be administered before, after or together with the compound of the invention, wherein said two other pharmacologically active substances are ⁇ a MEK inhibitor and a SOS1 inhibitor; or ⁇ trametinib and a SOS1 inhibitor; or ⁇ an anti-PD-1 antibody (preferably ezabenlimab) and an anti-LAG-3 antibody; or • an ant/-PD-1 antibody (preferably ezabenlimab) and a SOS1 inhibitor; or
  • a MEK inhibitor and an inhibitor selected from the group consisting of an EGFR inhibitor and/or ErbB2 (HER2) inhibitor and/or inhibitor of any mutants thereof; or
  • two other pharmacologically active substances are to be administered in combination with the compound of the invention wherein said two other pharmacologically active substances are
  • an anti-PD-1 antibody preferably ezabenlimab
  • an ant/- LAG-3 antibody preferably ezabenlimab
  • an anti-PD-1 antibody preferably ezabenlimab
  • SOS1 inhibitor a SOS1 inhibitor
  • a MEK inhibitor and an inhibitor selected from the group consisting of an EGFR inhibitor and/or ErbB2 (HER2) inhibitor and/or inhibitor of any mutants thereof; or
  • Additional pharmacologically active substance(s) which can also be used together/in combination with the compound of the invention - or a pharmaceutically acceptable salt thereof - or in the medical uses, uses, methods of treatment and/or prevention, pharmaceutical compositions, kits as herein (above and below) defined include, without being restricted thereto, hormones, hormone analogues and antihormones ⁇ e.g.
  • tamoxifen toremifene, raloxifene, fulvestrant, megestrol acetate, flutamide, nilutamide, bicalutamide, aminoglutethimide, cyproterone acetate, finasteride, buserelin acetate, fludrocortisone, fluoxymesterone, medroxyprogesterone, octreotide), aromatase inhibitors ⁇ e.g. anastrozole, letrozole, liarozole, vorozole, exemestane, atamestane), LHRH agonists and antagonists e.g.
  • growth factors such as for example platelet derived growth factor (PDGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), insuline-like growth factors (IGF), human epidermal growth factor (HER, e.g.
  • growth factors such as for example platelet derived growth factor (PDGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), insuline-like growth factors (IGF), human epidermal growth factor (HER, e.g.
  • PDGF platelet derived growth factor
  • FGF fibroblast growth factor
  • VEGF vascular endothelial growth factor
  • EGF epidermal growth factor
  • IGF insuline-like growth factors
  • HER human epidermal growth factor
  • inhibitors are for example (antZ-)growth factor antibodies, ⁇ anti- )growth factor receptor antibodies and tyrosine kinase inhibitors, such as for example cetuximab, gefitinib, afatinib, nintedanib, imatinib, lapatinib, bosutinib, bevacizumab and trastuzumab); antimetabolites ⁇ e.g.
  • antifolates such as methotrexate, raltitrexed, pyrimidine analogues such as 5-fluorouracil (5-Fll), ribonucleoside and deoxyribonucleoside analogues, capecitabine and gemcitabine, purine and adenosine analogues such as mercaptopurine, thioguanine, cladribine and pentostatin, cytarabine (ara C), fludarabine); antitumor antibiotics ⁇ e.g.
  • anthracyclins such as doxorubicin, doxil (pegylated liposomal doxorubicin hydrochloride, myocet (non-pegylated liposomal doxorubicin), daunorubicin, epirubicin and idarubicin, mitomycin-C, bleomycin, dactinomycin, plicamycin, streptozocin); platinum derivatives ⁇ e.g. cisplatin, oxaliplatin, carboplatin); alkylation agents ⁇ e.g.
  • epipodophyllotoxins such as for example etoposide and etopophos, teniposide, amsacrin, topotecan, irinotecan, mitoxantrone), serine/threonine kinase inhibitors ⁇ e.g.
  • PDK 1 inhibitors Raf inhibitors, A-Raf inhibitors, B- Raf inhibitors, C-Raf inhibitors, mTOR inhibitors, mTORC1/2 inhibitors, PI3K inhibitors, PI3Ka inhibitors, dual mTOR/PI3K inhibitors, STK 33 inhibitors, AKT inhibitors, PLK 1 inhibitors, inhibitors of CDKs, Aurora kinase inhibitors), tyrosine kinase inhibitors ⁇ e.g. PTK2/FAK inhibitors), protein protein interaction inhibitors ⁇ e.g.
  • IAP inhibitors/SMAC mimetics Mcl-1 , MDM2/MDMX
  • MEK inhibitors MEK inhibitors
  • ERK inhibitors FLT3 inhibitors
  • BRD4 inhibitors IGF-1 R inhibitors
  • TRAILR2 agonists Bcl-xL inhibitors, Bcl-2 inhibitors ⁇ e.g. venetoclax
  • Bcl-2/Bcl-xL inhibitors ErbB receptor inhibitors
  • BCR-ABL inhibitors BCR-ABL inhibitors
  • ABL inhibitors Src inhibitors
  • rapamycin analogs ⁇ e.g.
  • ipilimumab nivolumab, pembrolizumab
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • enhancers ⁇ e.g. anti-CD33 antibodies, anti- CD37 antibodies, anti-CD20 antibodies
  • t-cell engagers ⁇ e.g. bi-specific T-cell engagers (BiTEs®) like e.g. CD3 x BCMA, CD3 x CD33, CD3 x CD19), PSMA x CD3), tumor vaccines, immunomodulator, e.g.
  • STING agonist and various chemotherapeutic agents such as amifostin, anagrelid, clodronat, filgrastin, interferon, interferon alpha, leucovorin, procarbazine, levamisole, mesna, mitotane, pamidronate and porfimer.
  • chemotherapeutic agents such as amifostin, anagrelid, clodronat, filgrastin, interferon, interferon alpha, leucovorin, procarbazine, levamisole, mesna, mitotane, pamidronate and porfimer.
  • compositions, kits, methods, uses, pharmaceutical compositions or compounds for use according to this invention may envisage the simultaneous, concurrent, sequential, successive, alternate or separate administration of the active ingredients or components.
  • the compound of the invention and the one or more other pharmacologically active substance(s) can be administered formulated either dependently or independently, such as e.g. the compound of the invention and the one or more other pharmacologically active substance(s) may be administered either as part of the same pharmaceutical composition/dosage form or, preferably, in separate pharmaceutical compositions/dosage forms.
  • “combination” or “combined” within the meaning of this invention includes, without being limited, a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed ⁇ e.g. free) combinations (including kits) and uses, such as e.g. the simultaneous, concurrent, sequential, successive, alternate or separate use of the components or ingredients.
  • the term “fixed combination” means that the active ingredients are administered to a patient simultaneously in the form of a single entity or dosage.
  • non-fixed combination means that the active ingredients are administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the compounds in the body of the patient.
  • the administration of the compound of the invention and the one or more other pharmacologically active substance(s) may take place by co-administering the active components or ingredients, such as e.g. by administering them simultaneously or concurrently in one single or in two or more separate formulations or dosage forms.
  • the administration of the compound of the invention and the one or more other pharmacologically active substance(s) may take place by administering the active components or ingredients sequentially or in alternation, such as e.g. in two or more separate formulations or dosage forms.
  • simultaneous administration includes administration at substantially the same time.
  • This form of administration may also be referred to as “concomitant” administration.
  • Concurrent administration includes administering the active agents within the same general time period, for example on the same day(s) but not necessarily at the same time.
  • Alternate administration includes administration of one agent during a time period, for example over the course of a few days or a week, followed by administration of the other agent(s) during a subsequent period of time, for example over the course of a few days or a week, and then repeating the pattern for one or more cycles.
  • Sequential or successive administration includes administration of one agent during a first time period (for example over the course of a few days or a week) using one or more doses, followed by administration of the other agent(s) during a second and/or additional time period (for example over the course of a few days or a week) using one or more doses.
  • An overlapping schedule may also be employed, which includes administration of the active agents on different days over the treatment period, not necessarily according to a regular sequence. Variations on these general guidelines may also be employed, e.g. according to the agents used and the condition of the subject.
  • a pharmaceutical composition comprising a compound of the invention - or a pharmaceutically acceptable salt thereof - and one or more pharmaceutically acceptable excipient(s).
  • said pharmaceutical composition optionally comprises one or more other pharmacologically active substance(s).
  • Said one or more other pharmacologically active substance(s) may be the pharmacologically active substances or combination partners herein defined.
  • compositions for administering the compounds according to the invention will be apparent to those with ordinary skill in the art and include for example tablets, pills, capsules, suppositories, lozenges, troches, solutions, suspensions - particularly solutions, suspensions or other mixtures for parenteral administration (s.c., i.v., i.m., etc...) and infusion (injectables) - elixirs, syrups, sachets, emulsions, inhalatives or dispersible powders.
  • the content of the compounds of the invention should be in the range from 0.1 to 90 wt.-%, preferably 0.5 to 50 wt.-% of the composition as a whole, i.e. in amounts which are sufficient to achieve the dosage range specified below.
  • the doses specified may, if necessary, be given several times a day.
  • Suitable tablets may be obtained, for example, by mixing the compounds of the invention with known pharmaceutically acceptable excipients, for example inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and/or lubricants.
  • the tablets may also comprise several layers.
  • Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with excipients normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar.
  • excipients normally used for tablet coatings for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar.
  • the core may also consist of a number of layers.
  • the tablet coating may consist of a number of layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
  • Syrups or elixirs containing one or more compounds of the invention or combinations with one or more other pharmaceutically active substance(s) may additionally contain excipients like a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain excipients like suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
  • excipients like a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain excipients like suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene
  • Solutions for injection and infusion are prepared in the usual way, e.g. with the addition of excipients like isotonic agents, preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, optionally using emulsifiers and/or dispersants, whilst if water is used as the diluent, for example, organic solvents may optionally be used as solvating agents or dissolving aids, and transferred into injection vials or ampoules or infusion bottles.
  • excipients like isotonic agents, preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, optionally using emulsifiers and/or dispersants, whilst if water is used as the diluent, for example, organic solvents may optionally be used as solvating agents or dissolving aids, and transferred
  • Capsules containing one or more compounds of the invention or combinations with one or more other pharmaceutically active substance(s) may for example be prepared by mixing the compounds/active substance(s) with inert excipients such as lactose or sorbitol and packing them into gelatine capsules.
  • Suitable suppositories may be made for example by mixing with excipients provided for this purpose such as neutral fats or polyethyleneglycol or the derivatives thereof.
  • Excipients which may be used include, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolins, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silicic acid and silicates), sugars (e.g. cane sugar, lactose and glucose), emulsifiers (e.g.
  • pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolins, clays, talc, chalk), synthetic mineral powders (e.g. highly disper
  • lignin e.g. lignin, spent sulfite liquors, methylcellulose, starch and polyvinylpyrrolidone
  • lubricants e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulfate.
  • the pharmaceutical compositions are administered by the usual methods, preferably by oral or transdermal route, most preferably by oral route.
  • the tablets may of course contain, apart from the above-mentioned excipients, additional excipients such as sodium citrate, calcium carbonate and dicalcium phosphate together with various excipients such as starch, preferably potato starch, gelatine and the like.
  • additional excipients such as sodium citrate, calcium carbonate and dicalcium phosphate together with various excipients such as starch, preferably potato starch, gelatine and the like.
  • lubricants such as magnesium stearate, sodium lauryl sulfate and talc may be used at the same time for the tabletting process.
  • the active substances may be combined with various flavour enhancers or colourings in addition to the excipients mentioned above.
  • solutions of the active substances with suitable liquid excipients may be used.
  • the dosage range of the compounds of the invention applicable per day is usually from 1 mg to 2000 mg, preferably from 250 to 1250 mg.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising at least one (preferably one) compound of the invention - or a pharmaceutically acceptable salt thereof - and one or more pharmaceutically acceptable excipient(s).
  • the compounds of the invention and the pharmaceutical compositions comprising such compound and salts may also be co-administered with other pharmacologically active substances, e.g. with other anti-neoplastic compounds (e.g. chemotherapy), i.e. used in combination (see combination treatment further above).
  • other pharmacologically active substances e.g. with other anti-neoplastic compounds (e.g. chemotherapy), i.e. used in combination (see combination treatment further above).
  • the elements of such combinations may be administered (whether dependently or independently) by methods customary to the skilled person and as they are used in monotherapy, e.g. by oral, enteral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, transdermal or subcutaneous injection, or implant), nasal, vaginal, rectal, or topical routes of administration and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable excipients appropriate for each route of administration.
  • the combinations may be administered at therapeutically effective single or divided daily doses.
  • the active components of the combinations may be administered in such doses which are therapeutically effective in monotherapy, or in such doses which are lower than the doses used in monotherapy, but when combined result in a desired (joint) therapeutically effective amount.
  • the invention also relates to a pharmaceutical preparation comprising a compound of the invention - or a pharmaceutically acceptable salt thereof - and one or more (preferably one or two, most preferably one) other pharmacologically active substance(s).
  • a pharmaceutical composition comprising a compound of the invention - or a pharmaceutically acceptable salt thereof - and one or more (preferably one or two, most preferably one) other pharmacologically active substance(s).
  • compositions to be co-administered or used in combination can also be provided in the form of a kit.
  • the invention also relates to a kit comprising
  • a first pharmaceutical composition or dosage form comprising a compound of the invention and, optionally, one or more pharmaceutically acceptable excipient(s), and
  • a second pharmaceutical composition or dosage form comprising another pharmacologically active substance and, optionally, one or more pharmaceutically acceptable excipient(s).
  • such kit comprises a third pharmaceutical composition or dosage form comprising still another pharmacologically active substance and, optionally, one or more pharmaceutically acceptable excipient(s).
  • the indication of the number of members in groups that contain one or more heteroatom(s) relates to the total number of atoms of all the ring members or the total of all the ring and carbon chain members.
  • compound of the invention and grammatical variants thereof comprises compounds of formula (I), (I*), (I**), (I***), (I****), (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (II), (II*), (II**), (II***), (II****), (IIa), (II*a), (IIb), (II*b), (IIc), (II*c), (IId), (II*d), (IIe), (II*e) and (IIf) as well as compounds I-49, I-50 and I-51, including all salts, aspects and preferred embodiments thereof as herein defined.
  • a dotted line or a squiggly line may be used in sub-formulas to indicate the atom or bond which is connected to the core molecule as defined.
  • the substituent(s) of the core molecule to which the sub-formula is connected to may be specified, in particular on the side of the dotted line or squiggly line opposite to the side of the sub-formula.
  • C1-x-alkyl wherein x is an integer selected from 2, 3, 4, 5 or 6, preferably 3, 4, or 6, either alone or in combination with another radical, denotes an acyclic, saturated, branched or linear hydrocarbon radical with 1 to x C atoms.
  • C1-6-alkyl embraces the radicals H3C-, H3C-CH2-, H3C-CH2-CH2-, H3C-CH(CH3)-, H3C-CH2-CH2-CH2-, H3C-CH2-CH(CH3)-, H3C-CH(CH3)-CH2-, H3C-C(CH3)2-, H3C-CH2-CH2-CH2-CH2-CH(CH3)-, H3C-CH2-CH(CH3)-, H3C-CH2-CH(CH3)-, H3C-CH(CH3)-CH2-CH2-, H3C-CH2-C(CH3)2-, H3C-C(CH3)2-CH2-, H3C-CH(CH3)-CH(CH3)-, H3C-CH2-CH(CH2)-, H3C-CH(CH3)-CH(CH3)-, H3C-CH2-CH(CH2CH3)-, etc.
  • C1-x-alkyl refers to methyl, iso-propyl or tert-butyl.
  • C1-x-alkylene wherein x is an integer selected from 2, 3, 4, 5, 6, 7 or 8, preferably 3, 4 or 6, either alone or in combination with another radical, denotes an acyclic, saturated, branched or linear chain divalent alkyl radical containing from 1 to x carbon atoms.
  • C1-4-alkylene includes -CH2-, -CH2-CH2-, -CH(CH3)-, -CH2-CH2-CH2-, -C(CH3)2-, -CH(CH2CH3)-, -CH(CH 3)-CH2-, -CH2-CH(CH3)-, -CH2-CH2-CH2-CH2-, -CH2-CH2-CH(CH3)-, -CH(CH3)-CH2-CH2-, - CH 2 -CH(CH 3 )-CH 2 -, -CH 2 -C(CH 3 ) 2 -, -C(CH 3 ) 2 -CH 2 -, -CH(CH 3 )-CH(CH 3 )-, -CH 2 -CH(CH 2 CH 3 )-, -CH(CH 2 CH 3 )-CH 2 -, -CH(CH 2 CH 3 )-CH 2 -, -CH(CH 2 CH 3 )-CH 2 -, -CH(CH 2 CH 3 )-CH 2
  • alkyl By the terms propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl etc. without any further definition are meant saturated hydrocarbon groups with the corresponding number of carbon atoms, wherein all isomeric forms are included.
  • alkyl also applies if alkyl is a part of another (combined) group such as for example cyano-C 1-6 alkylamino or C x-y alkyloxy.
  • C x-y alkyloxy is sometimes abbreviated as C x-y alkoxy.
  • alkoxylene denotes a bivalent alkoxy radical.
  • alkenyl consists of at least two carbon atoms, wherein at least two adjacent carbon atoms are joined together by a C-C double bond and a carbon atom can only be part of one C-C double bond. If in an alkyl as hereinbefore defined having at least two carbon atoms, two hydrogen atoms on adjacent carbon atoms are formally removed and the free valencies are saturated to form a second bond, the corresponding alkenyl is formed.
  • alkenyl examples include vinyl (ethenyl), prop-1-enyl, allyl (prop-2-enyl), isopropenyl, but-1- enyl, but-2-enyl, but-3-enyl, 2-methyl-prop-2-enyl, 2-methyl-prop-1-enyl, 1-methyl-prop-2- enyl, 1-methyl-prop-1-enyl, 1 -methylidenepropyl, pent-1 -enyl, pent-2-enyl, pent-3-enyl, pent-4-enyl, 3-methyl-but-3-enyl, 3-methyl-but-2-enyl, 3-methyl-but-1-enyl, hex-1 -enyl, hex- 2-enyl, hex-3-enyl, hex-4-enyl, hex-5-enyl, 2,3-dimethyl-but-3-enyl, 2,3-dimethyl-but-2-enyl, 2-methyliden
  • propenyl includes prop-1 -enyl and prop-2-enyl
  • butenyl includes but-1-enyl, but-2-enyl, but-3-enyl, 1-methyl-prop-1-enyl, 1-methyl-prop-2-enyl etc.
  • Alkenyl may optionally be present in the cis or trans or E or Z orientation with regard to the double bond(s).
  • alkenyl also applies when alkenyl is part of another (combined) group such as for example in C x-y alkenylamino or C x-y alkenyloxy.
  • alkenylene consists of at least two carbon atoms, wherein at least two adjacent carbon atoms are joined together by a C-C double bond and a carbon atom can only be part of one C-C double bond. If in an alkylene as hereinbefore defined having at least two carbon atoms, two hydrogen atoms at adjacent carbon atoms are formally removed and the free valencies are saturated to form a second bond, the corresponding alkenylene is formed.
  • alkenylene examples include ethenylene, propenylene, 1 -methylethenylene, butenylene, 1- methylpropenylene, 1 ,1 -dimethylethenylene, 1 ,2-dimethylethenylene, pentenylene, 1 , 1 -dimethylpropenylene, 2,2-dimethylpropenylene, 1 ,2-dimethylpropenylene, 1 ,3-dimethylpropenylene, hexenylene etc.
  • propenylene, butenylene, pentenylene, hexenylene etc. without any further definition are meant all the conceivable isomeric forms with the corresponding number of carbon atoms, i.e.
  • propenylene includes 1 -methylethenylene and butenylene includes 1 -methylpropenylene, 2-methylpropenylene, 1 ,1 -dimethylethenylene and 1 ,2-dimethylethenylene.
  • Alkenylene may optionally be present in the cis or trans or E or Z orientation with regard to the double bond(s).
  • alkenylene also applies when alkenylene is a part of another (combined) group as for example in HO-C x-y alkenyleneamino or H2N-C x-y alkenyleneoxy.
  • alkynyl consists of at least two carbon atoms, wherein at least two adjacent carbon atoms are joined together by a C-C triple bond. If in an alkyl as hereinbefore defined having at least two carbon atoms, two hydrogen atoms in each case at adjacent carbon atoms are formally removed and the free valencies are saturated to form two further bonds, the corresponding alkynyl is formed.
  • alkynyl examples include ethynyl, prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, but-3-ynyl, 1-methyl-prop-2-ynyl, pent-1-ynyl, pent-2-ynyl, pent-3-ynyl, pent-4-ynyl, 3-methyl-but-1-ynyl, hex-1-ynyl, hex-2-ynyl, hex-3-ynyl, hex-4-ynyl, hex-5-ynyl etc.
  • propynyl includes prop-1 -ynyl and prop-2- ynyl
  • butynyl includes but-1-ynyl, but-2-ynyl, but-3-ynyl, 1-methyl-prop-1-ynyl,1-methyl- prop-2-ynyl, etc.
  • hydrocarbon chain carries both at least one double bond and also at least one triple bond, by definition it belongs to the alkynyl subgroup.
  • alkynyl also applies if alkynyl is part of another (combined) group, as for example in C x.y alkynylamino or C x.y alkynyloxy.
  • alkynylene consists of at least two carbon atoms, wherein at least two adjacent carbon atoms are joined together by a C-C triple bond. If in an alkylene as hereinbefore defined having at least two carbon atoms, two hydrogen atoms in each case at adjacent carbon atoms are formally removed and the free valencies are saturated to form two further bonds, the corresponding alkynylene is formed.
  • alkynylene examples include ethynylene, propynylene, 1-methylethynylene, butynylene, 1-methylpropynylene, 1 ,1-dimethylethynylene, 1 ,2-dimethylethynylene, pentynylene, 1,1-dimethylpropynylene, 2,2-dimethylpropynylene, 1,2-dimethylpropynylene, 1,3-dimethylpropynylene, hexynylene etc.
  • propynylene includes 1-methylethynylene and butynylene includes 1-methylpropynylene, 2-methylpropynylene, 1,1-dimethylethynylene and 1,2-dimethylethynylene.
  • alkynylene also applies if alkynylene is part of another (combined) group, as for example in HO-Cx-yalkynyleneamino or H2N-Cx-yalkynyleneoxy.
  • heteroatoms are meant oxygen, nitrogen and sulphur atoms.
  • Haloalkyl is derived from the previously defined alkyl by replacing one or more hydrogen atoms of the hydrocarbon chain independently of one another by halogen atoms, which may be identical or different.
  • Halogen denotes fluorine, chlorine, bromine and iodine.
  • C 3-k -cycloalkyl wherein k is 4 or 5, either alone or in combination with another radical, denotes a cyclic, saturated, unbranched hydrocarbon radical with 3 to k C atoms.
  • C 3-5 -cycloalkyl includes cyclopropyl, cyclobutyl and cyclopentyl.
  • the C 3-k - cycloalkyl may be linked as a substituent to the molecule via every suitable position of the ring system.
  • cycloalkyl also applies if cycloalkyl is part of another (combined) group as for example in C x-y cycloalkylamino, C x-y cycloalkyloxy or C x-y cycloalkylalkyl.
  • Heterocycloalkyl means a saturated or unsaturated mono- or polycyclic ring system optionally comprising aromatic rings, containing one or more heteroatoms selected from N, O, S, SO or SO 2 consisting of the specified number of atoms, wherein none of the heteroatoms is part of the aromatic ring (if present).
  • heterocycloalkyl is intended to include all the possible isomeric forms.
  • heterocycloalkyl By unsaturated is meant that there is at least one double bond in the ring system in question, but no (hetero)aromatic system is formed. If a heterocycloalkyl is substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on all the hydrogen-carrying carbon and/or nitrogen atoms. Heterocycloalkyl itself may be linked as a substituent to the molecule via every suitable position of the ring system. Substituents on heterocycloalkyl do not count for the number of members of a heterocycloalkyl.
  • heterocycloalkyl includes the following exemplary structures (not depicted as radicals as each form is optionally attached through a covalent bond to any atom so long as appropriate valences are maintained):
  • heterocycloalkylene is also derived from the previously defined heterocycloalkyl.
  • Heterocycloalkylene unlike heterocycloalkyl, is bivalent and requires two binding partners. Formally, the second valency is obtained by removing a hydrogen atom from a heterocycloalkylene.
  • Corresponding groups are for example: piperidinyl
  • heteroaryl means a mono- or polycyclic ring system, comprising at least one aromatic ring, containing one or more heteroatoms selected from N, O, S, SO or SO2, consisting of 5 to 14 ring atoms wherein at least one of the heteroatoms is part of an aromatic ring.
  • heteroaryl is intended to include all the possible isomeric forms.
  • heteroaryl includes the following exemplary structures (not depicted as radicals as each form is optionally attached through a covalent bond to any atom so long as appropriate valences are maintained):
  • heteroarylene refers to pyrrole, furan, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, thiadiazole and triazole, all of which include all the possible isomeric forms and may be linked as a substituent to the molecule via every suitable position of the ring system.
  • heteroarylene is also derived from the previously defined heteroaryl.
  • Heteroarylene unlike heteroaryl, is bivalent and requires two binding partners. Formally, the second valency is obtained by removing a hydrogen atom from a heteroaryl.
  • Corresponding groups are for example: pyrrolyl and etc.
  • heteroarylene also applies if heteroarylene is part of another (combined) group as for example in HO-heteroaryleneamino or H2N-heteroaryleneoxy.
  • substituted means that one or more hydrogens on the designated atom are replaced by a group selected from a defined group of substituents, provided that the designated atom's normal valence is not exceeded, and that the substitution results in a stable compound.
  • substituted may be used in connection with a chemical moiety instead of a single atom, e.g. “substituted alkyl”, or the like.
  • a given chemical formula or name shall encompass tautomers and all stereo, optical and geometrical isomers (e.g. enantiomers, diastereomers, E/Z isomers etc%) and racemates thereof as well as mixtures in different proportions of the separate enantiomers, mixtures of diastereomers, or mixtures of any of the foregoing forms where such isomers and enantiomers exist, as well as salts, including pharmaceutically acceptable salts thereof and solvates thereof such as for instance hydrates including solvates and hydrates of the free compound or solvates and hydrates of a salt of the compound.
  • substantially pure stereoisomers can be obtained according to synthetic principles known to a person skilled in the field, e.g. by separation of corresponding mixtures, by using stereochemically pure starting materials and/or by stereoselective synthesis. It is known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis, e.g. starting from optically active starting materials and/or by using chiral reagents.
  • Enantiomerically pure compounds of this invention or intermediates may be prepared via asymmetric synthesis, for example by preparation and subsequent separation of appropriate diastereomeric compounds or intermediates which can be separated by known methods (e.g. by chromatographic separation or crystallization) and/or by using chiral reagents, such as chiral starting materials, chiral catalysts or chiral auxiliaries.
  • phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, and commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salts refers to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • such salts include salts from benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gentisic acid, hydrobromic acid, hydrochloric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, 4-methyl- benzenesulfonic acid, phosphoric acid, salicylic acid, succinic acid, sulfuric acid and tartaric acid.
  • Further pharmaceutically acceptable salts can be formed with cations from ammonia, L- arginine, calcium, 2,2’-iminobisethanol, L-lysine, magnesium, /V-methyl-D-glucamine, potassium, sodium and tris(hydroxymethyl)-aminomethane.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base form of these compounds with a sufficient amount of the appropriate base or acid in water or in an organic diluent like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof.
  • Salts of other acids than those mentioned above which for example are useful for purifying or isolating the compounds of the present invention e.g. trifluoro acetate salts
  • Salts of other acids than those mentioned above which for example are useful for purifying or isolating the compounds of the present invention also comprise a part of the invention.
  • the letter A has the function of a ring designation in order to make it easier, for example, to indicate the attachment of the ring in question to other rings.
  • binding partners can be indicated at the end of a dotted line or in brackets where necessary for clarification purposes, as in the following representations:
  • Groups or substituents are frequently selected from among a number of alternative groups/substituents with a corresponding group designation e.g. R a , R b etc). If such a group is used repeatedly to define a compound according to the invention in different parts of the molecule, it is pointed out that the various uses are to be regarded as totally independent of one another.
  • a therapeutically effective amount for the purposes of this invention is meant a quantity of substance that is capable of obviating symptoms of illness or of preventing or alleviating these symptoms, or which prolong the survival of a treated patient.
  • the thin layer chromatography is carried out on ready-made silica gel 60 TLC plates on glass (with fluorescence indicator F-254) made by Merck.
  • the preparative high pressure chromatography (RP HPLC) of the example compounds according to the invention is carried out on Agilent or Gilson systems with columns made by Waters (names: SunFireTM Prep C18, OBDTM 10 pm, 50 x 150 mm or SunFireTM Prep C18 OBDTM 5 pm, 30 x 50 mm or XBridgeTM Prep C18, OBDTM 10 pm, 50 x 150 mm or XBridgeTM Prep C18, OBDTM 5 pm, 30 x 150 mm or XBridgeTM Prep C18, OBDTM 5 pm, 30 x 50 mm) and YMC (names: Actus-Triart Prep C18, 5 pm, 30 x 50 mm) and Chiralpak IE (5 pm, 250 x 20 mm)
  • the supercritical fluid chromatography (SFC) of the intermediates and example compounds according to the invention is carried out on a Agilent 1260 SFC-system, JASCO SFC-system or Sepiatec SFC-system or Waters Thar SFC-System or Waters UPC 2 -MS SFC-System with the following colums: Chiralcel OJ (250 x 20 mm, 5 pm), Chiralpak AD-H (21 x 250 mm), 5 pm, Chiralpak AD (250 x 20 mm, 5 pm), Chiralpak AS (250 x 20 mm, 5 pm), Chiralpak IC (250 x 20 mm, 5 pm), Chiralpak IA (250 x 20 mm, 5 pm), Chiralcel OJ (250 x 20 mm, 5 pm), Chiralcel OD (250 x 20 mm, 5 pm), Chiralcel OX-3 (150 x 4.6 mm, 3 pm), Phenomenex Lux C2 (250 x 20 mm, 5 pm).
  • SFC supercritical fluid
  • the analytical HPLC (reaction control) of intermediate and final compounds is carried out using columns made by Waters (names: XBridgeTM C18, 2.5 pm, 2.1 x 20 mm orXBridgeTM C18, 2.5 pm, 2.1 x30 mm orAquity LIPLC BEH C18, 1.7 pm, 2.1 x 50mm) and YMC (names: Triart C18, 3.0 pm, 2.0 x 30 mm) and Phenomenex (names: Luna C18, 5.0 pm, 2.0 x 30 mm).
  • the analytical equipment is also equipped with a mass detector in each case.
  • MSD signal settings Scan pos/neg 150 - 750 Detection signal UV 254 nm, 230 nm, 214 nm (bandwidth 8, reference off) Spectrum range: 190 - 400 nm; slit: 4 nm Peak width > 0.0031 min (0.063 s response time, 80Hz)
  • MSD signal settings Scan pos/neg 700 - 1350 Detection signal UV 254 nm, 230 nm, 214 nm (bandwidth 10, reference off) Spectrum range: 190 - 400 nm; slit: 4 nm Peak width > 0.0031 min (0.063 s response time, 80Hz)
  • Solvent A 5 mM ammonium acetate in water / 0.05% formic acid in water
  • Solvent A: 0.1 % formic acid in water; B: 0.1 % formic acid in ACN
  • Solvent A: 0.1 % formic acid in water; B: 0.1 % formic acid in ACN
  • K-4a (21.10 g, 75.93 mmol, 80 % purity, 1.0 eq.) is mixed with /V,/V-dimethylformamide dimethyl acetal (57.6 g, 454.37 mmol, 94 % purity, 6.0 eq.) and is irradiated in an ultrasound bath for 15 min until the mixture is a clear solution.
  • Water 200 mL is added and the reaction mixture is stirred for 30 min at rt until a precipitate forms.
  • the precipitate is filtered and water (100 mL) is added.
  • the mixture is irradiated in an ultrasound bath for 15 min and the precipitate is filtered.
  • the precipitate is washed with isopropanol (25 mL) and dried under vacuum at 45 °C over night to give K-5a which is used for the next steps without further purification.
  • intermediate K-21a (20.00 g, 52.84 mmol, 1.0 eq.) in DCM (100 mL) is added HCI (200 mL, 4 N in 1 ,4 dioxane) and the reaction mixture is stirred at rt for 4 h. After complete conversion the volatiles are removed under reduced pressure to get the crude product. The crude product is triturated with pentane to afford intermediate K-22a which is used in next step without any other purification.
  • reaction mixture is allowed to cool to room temperature and is diluted with water and EtOAc and stirred for 15 min. The phases are separated and the aqueaous layer is extracted with EtOAc (3 x). The combined organic layers are washed with saturated aqueous NaCI solution and the solvent is removed under reduced preasure. The crude product is purified by chromatography to obtain A-1a.
  • intermediate A-5a (1.00 g, 3.263 mmol, 1.0 eq.) in THF (5 mL) at 0 °C is added allylmagnesium bromide (4.89 mL, 4.8945 mmol, 1.5 eq. 1.0 M in Et20).
  • the reaction was warmed to rt and stirred for 16 h.
  • the reaction mixture was diluted with ice water (10 mL) and the resulting precipitate was filtered and washed with water.
  • the filtrate was extracted with DCM (2 x 10 mL) and the combined organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure.
  • the crude product was purified by chromatography to give intermediate A-6a (table 31).
  • a stirred solution of Sml2 (0.1 M in THF, 27.4 mL, 2.74 mmol, 3.0 eq) is cooled to -78 °C and a solution of A-5a (280 mg, 0.91 mmol, 1.0 eq.) and ten drops of acetaldehyde in dry tBuOH (171.5 ⁇ L, 1 .83 mmol, 2.0 eq) and dry THF (11 .0 mL) is added in portions over 0.5 h at -78 °C and stirring is contiuend for 2 h at -78 °C. The reaction mixture is quenched with 10 % aqueous sodium thiosulfate solution and DCM is added.
  • a white percipitate is formed wich is filtered of over Celite. The phases are separarted and the aqueous phase is extracted three times with DCM. The combined organic layer is dried over magnesium sulfate and concentrated under reduce pressure. The crude product is purified by chromatography to abtain A-7a (table 32) as the main product with a de of 78% which is improved to 98% by chiral chromatography. Table 32
  • intermediate A-6a (1.00 g, 2.869 mmol, 1.0 eq.) in MeOH (10 mL) at - 78°C is purged with ozone gas for 30 min.
  • Sodium borohydrate (0.370, 10.042 mmol, 3.5 eq.) is added at -78°C and the mixture is allowed to warm to rt over night.
  • the reaction mixture is quenched with ice cold water and extrachted with DCM.
  • the organic layer is dried over sodium sulfate, filitered and concentrated under reduced preasue.
  • the crude product is purified by chromatography to give intermediate A-8a (table 33).
  • intermediate A-7a 105 mg, 0.298 mmol, 1.0 eq.
  • THF 1.2 mL
  • HCI 0.6 mL, 2 M in H2O
  • the reaction is diluted with MeOH and purified with an ionexchange column chromatography (Isolute SPE 1 g column, SCX-2) to give intermediate A-9a.
  • reaction mixture is filtered and cooled to - 78 °C under argon.
  • Isopropyl-magnesiumbromide (0.8 M in THF, 10.65 mL, 8.52 mmol, 6.0 eq.) is added dropwise over a perid of 1 h.
  • the reaction mixture is stirred at - 78 °C for 1 h.
  • After conversion the reaction mixture is quenched with water and DCM is added and the mixture is filtered. The phases are seperated and the organic layer is dried over magnesium sulfate and concentrated under reduce pressure.
  • the crude product is purified by chromatography to give intermediate A-12a (table 38).
  • intermediate E-6a (40.00 g, 0.13 mol, 1.0 eq.) in THF (800 ml) is added n-butyllithium solution (13 mL, 0.33 mol, 2.5 eq, 2.5 M in hexanes) at -78 °C and stirred at -40 °C for 2 h. After complete conversion the mixture is quenched with saturated ammonium chloride solution and diluted with ice cold water. The aqueous solution extracted with EtOAc (3 x). The combined organic layer is washed with water and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford the crude product. The crude product is purified by column chromatography yielding intermediate E- 7a.
  • intermediate E-7a To a stirred solution of intermediate E-7a (5.81 g, 25.44 mmol, 1.0 eq.) in DMF (20 ml) and water (20 ml) is added methyl (2R)-2-azido-3-methylbutanoate (4.00 g, 25.44 mmol, 1.0 eq.), sodium L-ascorbate (2.52 g, 12.73 mmol, 0.5 eq) and copper(ll) sulfate pentahydrate (0.88 g, 2.54 mmol, 0.1 eq) at rt.
  • the reaction mixture is heated to 80 °C and stirred for 3 h.
  • the reaction mixture was poured into water and the aqueous layer was extracted with EtOAc (3 x). The combined organic layer is dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford the crude product.
  • the crude product is purified by chromatography to yield intermediate E-8a.
  • the mixture is cooled to 0°C and water (100 mL), sodium ascorbate (0.51 g, 003 mol, 0.1 eq.), copper(ll) sulfate pentahydrate (1.28 g, 0.225 mol, 0.2 eq.), and hept-6-yn-1-ol (2.871 g, 0.026 mmol, 1.0 eq.) are added.
  • the mixture is allowed to warm to rt and is stirred for 16 hours.
  • the reaction mixture was poured into water (500 mL) and the mixture was extracted with ethyl acetate (3x 400 mL).
  • the combined organic layer is washed with saturated aqueous NaHCOs solution (2 x 200 mL), dried over Na2SO4, and concentrated under reduced pressure.
  • the crude product is purified by chromatography to obtain intermediate E-9c (table 49).
  • intermediate E-2p (1.33 g, 1.705 mmol, 1.0 eq.) in MeOH (25 mL) in a hydrogenation reactor is added Pd/C (10%, 350.00 mg). The reaction mixture stirred under a pressure of 8 bar H2 for 8 h. After complete conversion the reaction mixture is filtered, and the solvent is removed under reduced pressure to give intermediate E-3p.
  • DMSO 1.0 mL
  • TEA 26 ⁇ L, 0.187 mmol, 5.8 eq.
  • the reaction mixture is stirred at rt for 20 min. After complete conversion the reaction mixture is diluted with ACN and purified by chromatograph yielding 1-16.
  • compounds I are obtained as mixtures of diastereomers they can be separated to single stereoisomers by chiral chromatography, e.g. as shown for 1-1 which was separated to obtain I-24 and I-25, I-3 which was separated into I-26 and I-27, I-35 which was separated to obtain I-40 and 1-41 , I-36 which was separated to obtain I-42 and I-43, as well as I-37 which was separated to obtain I-44 and I-45 (Table 61).
  • HATU 50 mg, 0.13 mmol, 1.8 eq.
  • HOAt 18 mg, 0.13 mmol, 1.8 qe.
  • (2S,4R)-1-[(2S)-2-amino- 3,3-dimethylbutanoyl]-4-hydroxy-N- ⁇ [4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl ⁇ pyrrolidine -2-carboxamide hydrochloride 43 mg, 0.073 mmol, 1.8 eq.
  • DIPEA 35 ⁇ L, 0.21 mmol
  • a HiBit protein detection tag (amino acid sequence VSGWRLFKKIS, Seq ID No 1) was introduced immediately downstream of the initiating Methionine codon of the endogenous
  • KRAS locus (Ensembl gene ID ENSG00000133703.7) of GP5d cells (ECACC Cat. No. 95090715) by CRISPR-based genome engineering using a KRAS(G12D) mutant donor construct encoding the HiBit tag. This resulted in the heterozygous introduction of an N- terminal HiBit tagged version of KRAS(G12D) into the KRAS(WT) allele. Correct modification of the KRAS locus was assessed by PCR-based genotyping and Sanger sequencing of the isolated PCR products. The resulting cell line is referred to as GP5d- HiBit-KRAS(G12D).
  • GP5d-HiBit-KRAS(G12D) cells were seeded at 25000 cells per well in 100 ⁇ L Dulbecco’s Modified Eagle medium (Sigma cat. no. D6429) supplemented with 10 % fetal calf serum into white bottom opaque 96 well plates (Perkin Elmer cat no. 5680). Plates were incubated at 37 °C, 5 % CO2 in a humidified incubator over night to allow the cells to adhere. Test compounds (10 mM stock in DMSO) were added at logarithmic dose series using the HP Digital Dispenser D300 (Tecan), normalizing for added DMSO.
  • the therapeutically relevant mutant KRAS constructs (WT, G12C, G12D, G12V, G13D) were obtained by site directed mutagenesis using a KRAS4B WT cDNA construct as a template.
  • GP5d cells (ECACC Cat. No. 95090715) were transduced with lentiviral vectors expressing mutant KRAS4B cDNA under control of a CMV promoter. Stably transduced cells were selected using a neomycin selectable marker encoded on the construct.
  • GP5d cells stably transduced with KRAS4B constructs as described above were seeded at 25000 cells per well in 100 ⁇ L Dulbecco’s Modified Eagle medium (Sigma cat. no. D6429) supplemented with 10 % fetal calf serum into white bottom opaque 96 well plates (Perkin Elmer cat no. 5680). Plates were incubated at 37 °C, 5 % CO2 in a humidified incubator over night to allow the cells to adhere. Test compounds (10 mM stock in DMSO) were added at logarithmic dose series using the HP Digital Dispenser D300 (Tecan), normalizing for added DMSO.
  • DC50 values were computed using a four parametric logistic model and are reported in nM in Table 65 for representative example (Ex.) compounds of the invention. Dmax values represent the maximal extent of degradation observed and is stated as percent of control (%Ctrl.) treatments in Table 66 for representative example (Ex.) compounds of the invention.
  • NCI-H358 cells are dispensed into white bottom opaque 96 well plates (Perkin Elmer cat no. 5680) at a density of 2000 cells per well in 100 ⁇ L RPMI-1640 ATCC-Formulation (Gibco # A10491) + 10 % FCS (fetal calf serum) (assay 1) or into black 384-well plates, flat and clear bottom (Greiner, PNr. 781091) at a density of 200 cells per well in 60 pl RPMI-1640 ATCC-Formulation (Gibco# A10491) + 10 % FCS (fetal calf serum) (assay 2).
  • the CTG assay is designed to measure quantitatively the proliferation of AsPC-1 cells (ATCC CRL-5985), using the CellTiter Glow Assay Kit (Promega G7571).
  • Cells are grown in RPMI medium (ATCC) supplemented with Fetal Calf Serum (Life Technologies, Gibco BRL, Cat. No. 10270-106).
  • ATCC RPMI medium
  • Fetal Calf Serum Life Technologies, Gibco BRL, Cat. No. 10270-106.
  • day 0 2000 AsPC-1 cells are seeded in 60 ⁇ L RPMI ATCC+10 % FCS+ Penstrep in a 384-well plate, flat and clear bottom (Greiner, PNr. 781091). Cells are then incubated in the plates at 37 °C in a CO2 incubator overnight.
  • GP2D cells (ATCC No. CRL-5807) are dispensed into white 384-well plates, flat and white bottom (Perkin Elmer, 6007680) at a density of 500 cells per well in 40 pl DM EM (Sigma, D6429) + 1x GlutaMAX (Gibco, 35050038) + 10 % FCS (fetal calf serum). Cells are incubated overnight at 37 °C in a humidified tissue culture incubator at 5 % CO2. Compounds (10 mM stock in DMSO) are added at logarithmic dose series using the HP Digital Dispenser D300 (Tecan), including DMSO controls and normalizing for added DMSO. For the TO time point measurement, untreated cells are analyzed at the time of compound addition.
  • SAS cells (JCRB0260) are dispensed into 384-well plates, flat and clear bottom (Greiner, PNr. 781091) at a density of 300 cells per well in 60 ⁇ L DMEM:F12 (Gibco 31330-038) + 10% Fetal Calf Serum (HyClone, PNr.: SH30084.03) and incubated at 37 °C in a CO2 incubator overnight. The next day, compounds (10 mM stock in DMSO) are added with the ECHO acoustic liquid handler system (Beckman Coulter), including DMSO controls.
  • Viability (stated as percent of control) is defined as relative luminescence units RLU of each well divided by the RLU of cells in DMSO controls. IC50 values are determined from viability measurements by non-linear regression using a four-parameter model.
  • SK-CO-1 cells (ATCC HTB-39) are dispensed into 384-well plates, flat and clear bottom (Greiner, PNr. 781091) at a density of 500 cells per well in 60 ⁇ L EMEM (Sigma M5650) + 10% Fetal Calf Serum (HyClone, PNr.: SH30084.03) and incubated at 37 °C in a CO2 incubator overnight. The next day, compounds (10 mM stock in DMSO) are added with the ECHO acoustic liquid handler system (Beckman Coulter), including DMSO controls.
  • ECHO acoustic liquid handler system Beckman Coulter
  • Viability (stated as percent of control) is defined as relative luminescence units RLU of each well divided by the RLU of cells in DMSO controls. IC50 values are determined from viability measurements by non-linear regression using a four-parameter model.
  • LOVO cells (ATCC CCL-229) are dispensed into 384-well plates, flat and clear bottom (Greiner, PNr. 781091) at a density of 1000 cells per well in 60 ⁇ L DMEM (Sigma D6429) + 10% Fetal Calf Serum (HyClone, PNr.: SH30084.03) and incubated at 37 °C in a CO2 incubator overnight. The next day, compounds (10 mM stock in DMSO) are added with the ECHO acoustic liquid handler system (Beckman Coulter), including DMSO controls.
  • Viability (stated as percent of control) is defined as relative luminescence units RLU of each well divided by the RLU of cells in DMSO controls. IC50 values are determined from viability measurements by non-linear regression using a four-parameter model.
  • GP5d cells (ECACC 95090715) are dispensed into white bottom opaque 96 well plates at a density of 5000 cells per well in 100 ⁇ L DM EM (BioWhittaker, Cat# BE12-605F) supplemented with 10 % FCS. Cells are incubated overnight at 37 °C in a humidified tissue culture incubator at 5 % CO2. Compounds (10 mM stock in DMSO) are added at logarithmic dose series using the HP Digital Dispenser D300 (Tecan), normalizing for added DMSO. For the TO time point measurement, untreated cells are analysed at the time of compound addition.
  • Viability (stated as percent of control) is defined as relative luminescence units RLU of each well divided by the RLU of cells in DMSO controls. IC50 values were computed from relative viability values using a four parametric logistic model.
  • SW620 cells (ATCC CCL-227) are dispensed into white bottom opaque 96 well plates (Perkin Elmer cat no. 5680) at a density of 2000 cells per well in 100 ⁇ L DMEM (BioWhittaker, Cat# BE12-605F) supplemented with 10 % FCS. Cells are incubated overnight at 37 °C in a humidified tissue culture incubator at 5 % CO2. Compounds (10 mM stock in DMSO) are added at logarithmic dose series using the HP Digital Dispenser D300 (Tecan), normalizing for added DMSO. For the TO time point measurement, untreated cells are analysed at the time of compound addition.
  • Viability (stated as percent of control) is defined as relative luminescence units RLU of each well divided by the RLU of cells in DMSO controls. IC50 values were computed from relative viability values using a four parametric logistic model.
  • A375 cells (ATCC CRL-1619) are dispensed into 384-well plates, flat and clear bottom (Greiner, PNr. 781091) at a density of 300 cells per well in 60 ⁇ L DMEM (Sigma D6429) + 10% Fetal Calf Serum (HyClone, PNr.: SH30084.03) and incubated at 37 °C in a CO2 incubator overnight. The next day, compounds (10 mM stock in DMSO) are added at logarithmic dose series using the HP Digital Dispenser D300 (Tecan), including DMSO controls.
  • Viability (stated as percent of control) is defined as relative luminescence units RLU of each well divided by the RLU of cells in DMSO controls. IC50 values are determined from viability measurements by non-linear regression using a four-parameter model.
  • IC50 values of representative compounds according to the invention measured with these assays in the indicated cell lines are presented in table 67.
  • the finely ground active substance, lactose and some of the corn starch are mixed together.
  • the mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried.
  • the granules, the remaining corn starch and the magnesium stearate are screened and mixed together.
  • the mixture is compressed to produce tablets of suitable shape and size.
  • the finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate which is dried and screened.
  • the sodiumcarboxymethyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size.
  • the active substance, lactose and cellulose are mixed together.
  • the mixture is screened, then either moistened with water, kneaded, wet-granulated and dried or dry-granulated or directely final blend with the magnesium stearate and compressed to tablets of suitable shape and size.
  • additional lactose or cellulose and magnesium stearate is added and the mixture is compressed to produce tablets of suitable shape and size.
  • the active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic.
  • the solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion.
  • the ampoules contain 5 mg, 25 mg and 50 mg of active substance.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/EP2022/083950 2021-12-01 2022-11-30 Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes Ceased WO2023099620A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN202280089389.4A CN118591540A (zh) 2021-12-01 2022-11-30 包含环状2-氨基-3-氰基噻吩的kras降解化合物
US18/715,145 US20250145608A1 (en) 2021-12-01 2022-11-30 Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
JP2024532456A JP2024542692A (ja) 2021-12-01 2022-11-30 環化２－アミノ－３－シアノチオフェンを含むｋｒａ分解化合物
EP22826087.3A EP4441051A1 (en) 2021-12-01 2022-11-30 Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163284751P 2021-12-01 2021-12-01
US63/284,751 2021-12-01

Publications (1)

Publication Number Publication Date
WO2023099620A1 true WO2023099620A1 (en) 2023-06-08

Family

ID=84537055

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/083950 Ceased WO2023099620A1 (en) 2021-12-01 2022-11-30 Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes

Country Status (5)

Country Link
US (1) US20250145608A1 (https=)
EP (1) EP4441051A1 (https=)
JP (1) JP2024542692A (https=)
CN (1) CN118591540A (https=)
WO (1) WO2023099620A1 (https=)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912723B2 (en) 2022-02-09 2024-02-27 Quanta Therapeutics, Inc. KRAS modulators and uses thereof
US11945812B2 (en) 2020-06-02 2024-04-02 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US12060367B2 (en) 2021-12-01 2024-08-13 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US12145947B2 (en) 2022-05-25 2024-11-19 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
WO2025016899A1 (en) 2023-07-19 2025-01-23 Bayer Aktiengesellschaft Spirocyclic compounds for the treatment of cancer
WO2025026903A1 (en) 2023-07-31 2025-02-06 Bayer Aktiengesellschaft Imidazo pyrimidine compounds for the treatment of cancer
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
US12404285B2 (en) 2022-05-06 2025-09-02 PAQ Therapeutics Inc. KRAS G12D proteolysis targeting chimeras
US12421254B2 (en) 2023-03-15 2025-09-23 Quanta Therapeutics, Inc. KRAS modulators and uses thereof
US12448399B2 (en) 2023-01-26 2025-10-21 Arvinas Operations, Inc. Cereblon-based KRAS degrading PROTACs and uses related thereto
US12466840B2 (en) 2023-10-20 2025-11-11 Merck Sharp & Dohme Llc Small molecule inhibitors of KRAS proteins
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
US12552783B2 (en) 2018-04-04 2026-02-17 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
US12599672B2 (en) 2023-10-03 2026-04-14 PAQ Therapeutics Inc. KRAS proteolysis targeting chimeras

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010066868A2 (en) 2008-12-12 2010-06-17 Boehringer Ingelheim International Gmbh Anti-igf antibodies
WO2013134243A1 (en) 2012-03-07 2013-09-12 Eli Lilly And Company 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors
WO2013136249A1 (en) 2012-03-14 2013-09-19 Lupin Limited Heterocyclyl compounds as mek inhibitors
WO2014151616A1 (en) 2013-03-14 2014-09-25 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2015155332A1 (en) 2014-04-11 2015-10-15 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors
WO2016001376A1 (en) 2014-07-03 2016-01-07 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
WO2016026937A1 (en) 2014-08-21 2016-02-25 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
WO2017060431A1 (en) 2015-10-09 2017-04-13 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
WO2018115380A1 (en) 2016-12-22 2018-06-28 Boehringer Ingelheim International Gmbh Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
WO2018140599A1 (en) * 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018172250A1 (en) 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
WO2018204532A1 (en) 2017-05-03 2018-11-08 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
WO2019122129A1 (en) 2017-12-21 2019-06-27 Boehringer Ingelheim International Gmbh Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
WO2019195609A2 (en) * 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
WO2019201848A1 (en) 2018-04-18 2019-10-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
WO2020180770A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2021118877A1 (en) * 2019-12-11 2021-06-17 Eli Lilly And Company Kras g12c inhibitors
WO2021186324A1 (en) 2020-03-16 2021-09-23 Novartis Ag Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors
WO2021207172A1 (en) * 2020-04-06 2021-10-14 Arvinas Operations, Inc. Compounds and methods for targeted degradation of kras
WO2021222138A1 (en) * 2020-04-27 2021-11-04 Development Center For Biotechnology Compounds for mutant ras protein degradation
WO2021245055A1 (en) * 2020-06-02 2021-12-09 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010066868A2 (en) 2008-12-12 2010-06-17 Boehringer Ingelheim International Gmbh Anti-igf antibodies
WO2013134243A1 (en) 2012-03-07 2013-09-12 Eli Lilly And Company 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors
WO2013136249A1 (en) 2012-03-14 2013-09-19 Lupin Limited Heterocyclyl compounds as mek inhibitors
WO2013136254A1 (en) 2012-03-14 2013-09-19 Lupin Limited Heterocyclyl compounds
WO2014151616A1 (en) 2013-03-14 2014-09-25 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2015155332A1 (en) 2014-04-11 2015-10-15 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors
WO2016001376A1 (en) 2014-07-03 2016-01-07 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
WO2016026937A1 (en) 2014-08-21 2016-02-25 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
WO2017060431A1 (en) 2015-10-09 2017-04-13 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
WO2018115380A1 (en) 2016-12-22 2018-06-28 Boehringer Ingelheim International Gmbh Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
WO2018140599A1 (en) * 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018172250A1 (en) 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
WO2018204532A1 (en) 2017-05-03 2018-11-08 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
WO2019122129A1 (en) 2017-12-21 2019-06-27 Boehringer Ingelheim International Gmbh Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
WO2019195609A2 (en) * 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
WO2019201848A1 (en) 2018-04-18 2019-10-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
WO2020180770A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2021118877A1 (en) * 2019-12-11 2021-06-17 Eli Lilly And Company Kras g12c inhibitors
WO2021186324A1 (en) 2020-03-16 2021-09-23 Novartis Ag Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors
WO2021207172A1 (en) * 2020-04-06 2021-10-14 Arvinas Operations, Inc. Compounds and methods for targeted degradation of kras
WO2021222138A1 (en) * 2020-04-27 2021-11-04 Development Center For Biotechnology Compounds for mutant ras protein degradation
WO2021245055A1 (en) * 2020-06-02 2021-12-09 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2021245051A1 (en) * 2020-06-02 2021-12-09 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer

Non-Patent Citations (31)

* Cited by examiner, † Cited by third party
Title
AWAD MMLIU SRYBKIN, IIARBOUR KCDILLY JZHU VW ET AL.: "Acquired resistance to KRAS(G12C) inhibition in cancer.", N ENGL J MED, vol. 384, 2021, pages 2382 - 93, XP055920424, DOI: 10.1056/NEJMoa2105281
BOND MICHAEL J. ET AL: "Targeted Degradation of Oncogenic KRAS G12C by VHL-Recruiting PROTACs", ACS CENTRAL SCIENCE, vol. 6, no. 8, 26 August 2020 (2020-08-26), pages 1367 - 1375, XP055866207, ISSN: 2374-7943, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453568/pdf/oc0c00411.pdf> DOI: 10.1021/acscentsci.0c00411 *
BONDESON, D.P. ET AL., CELL CHEMICAL BIOLOGY, vol. 25, 2018, pages 78 - 87
BONDESON, D.P. ET AL., NAT. CHEM. BIO., vol. 11, 2015, pages 611
CHARDIN ET AL., SCIENCE, vol. 260, no. 5112, 1993, pages 1338 - 43
COLLINS, I. ET AL., BIOCHEM J., vol. 474, 2017, pages 1127 - 1147
COX ET AL., NAT. REV. DRUG DISCOV., vol. 13, no. 11, 2014, pages 828 - 51
EBERLEIN ET AL., CANCER RES., vol. 7, no. 12, 2015, pages 2489 - 500
GADD, M.S. ET AL., NATURE CHEMICAL BIOLOGY, vol. 13, 2017, pages 514 - 521
GECHIJIAN, L.N. ET AL., NAT. CHEM. BIO., vol. 14, no. 7, 2018, pages 405 - 412
HERDEIS ET AL., CURR OPIN STRUCT BIOL., vol. 71, 2021, pages 136 - 147
HUGHES, S.J.CIULLI, A, ESSAYS BIOCHEM., vol. 61, 2017, pages 505 - 516
HUNTER ET AL., MOL. CANCER RES., vol. 13, no. 9, 2015, pages 1325 - 35
KARGBO ROBERT B.: "PROTAC-Mediated Degradation of KRAS Protein for Anticancer Therapeutics", ACS MEDICINAL CHEMISTRY LETTERS, vol. 11, no. 1, 23 December 2019 (2019-12-23), US, pages 5 - 6, XP055982838, ISSN: 1948-5875, DOI: 10.1021/acsmedchemlett.9b00584 *
LETO ET AL., J. MOL. MED. (BERL)., vol. 92, no. 7, July 2014 (2014-07-01), pages 709 - 22
LI LING ET AL: "Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity", BIOORGANIC CHEMISTRY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 117, 22 October 2021 (2021-10-22), XP086869944, ISSN: 0045-2068, [retrieved on 20211022], DOI: 10.1016/J.BIOORG.2021.105447 *
MCCORMICK ET AL., EXPERT OPIN. THER. TARGETS., vol. 19, no. 4, 2015, pages 451 - 4
MCCORMICK ET AL., J. MOL. MED. (BERL)., vol. 94, no. 3, 2016, pages 253 - 8
MCCORMICK ET AL., J. MOL. MED. (BERL, vol. 94, no. 3, 2016, pages 253 - 8
MEYERS ET AL., NAT GENET., vol. 49, 2017, pages 1779 - 1784
NAUMANN ET AL., PHARMAZIE, vol. 51, 1996, pages 4
NIMNUAL ET AL., SCI. STKE., vol. 2002, no. 145, 2002, pages 36
ORTIZ-CUARAN ET AL., CLIN. CANCER RES., vol. 22, no. 19, 2016, pages 4837 - 47
RODRIGUEZ-VICIANA ET AL., CANCER CELL, vol. 7, no. 3, 2005, pages 205 - 6
TANAKA NLIN JJLI CRYAN MBZHANG JKIEDROWSKI LA ET AL.: "Clinical acquired resistance to KRAS(G12C) inhibition through a novel KRAS switch-ll pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation.", CANCER DISCOV, vol. 11, 2021, pages 1913 - 22, XP055950929, DOI: 10.1158/2159-8290.CD-21-0365
TOURE, M.CREWS, C.M., ANGEW. CHEM. INT. ED. ENGL., vol. 55, 2016, pages 1966 - 1973
WINTER, G.E. ET AL., SCIENCE, vol. 348, 2015, pages 1376 - 1381
WONG ET AL., NAT MED., vol. 24, no. 7, 2018, pages 968 - 977
YOUNG ET AL., ADV. CANCER RES., vol. 102, 2009, pages 1 - 17
Z. YAO, NATURE, vol. 548, 2017, pages 234 - 238
ZENGERLE, M. ET AL., ACS CHEMICAL BIOLOGY, vol. 10, 2015, pages 1770 - 1777

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12552783B2 (en) 2018-04-04 2026-02-17 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
US11945812B2 (en) 2020-06-02 2024-04-02 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US12545670B2 (en) 2020-06-02 2026-02-10 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US12060367B2 (en) 2021-12-01 2024-08-13 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US11912723B2 (en) 2022-02-09 2024-02-27 Quanta Therapeutics, Inc. KRAS modulators and uses thereof
US12404285B2 (en) 2022-05-06 2025-09-02 PAQ Therapeutics Inc. KRAS G12D proteolysis targeting chimeras
US12145947B2 (en) 2022-05-25 2024-11-19 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
US12448399B2 (en) 2023-01-26 2025-10-21 Arvinas Operations, Inc. Cereblon-based KRAS degrading PROTACs and uses related thereto
US12421254B2 (en) 2023-03-15 2025-09-23 Quanta Therapeutics, Inc. KRAS modulators and uses thereof
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025016899A1 (en) 2023-07-19 2025-01-23 Bayer Aktiengesellschaft Spirocyclic compounds for the treatment of cancer
WO2025026903A1 (en) 2023-07-31 2025-02-06 Bayer Aktiengesellschaft Imidazo pyrimidine compounds for the treatment of cancer
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US12599672B2 (en) 2023-10-03 2026-04-14 PAQ Therapeutics Inc. KRAS proteolysis targeting chimeras
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
US12466840B2 (en) 2023-10-20 2025-11-11 Merck Sharp & Dohme Llc Small molecule inhibitors of KRAS proteins
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Also Published As

Publication number Publication date
CN118591540A (zh) 2024-09-03
EP4441051A1 (en) 2024-10-09
US20250145608A1 (en) 2025-05-08
JP2024542692A (ja) 2024-11-15

Similar Documents

Publication Publication Date Title
EP4441051A1 (en) Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
EP4157837B1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
EP4441050A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN115485277B (zh) 作为HER2抑制剂的[1,3]二嗪基[5,4-d]嘧啶
EP4100409B1 (en) [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
WO2023099623A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
EP4441053A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
EP4441056A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
EP4441055A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2024246099A1 (en) Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2019122129A1 (en) Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
HK40097417A (en) Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
HK40122799A (en) [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
EA047617B1 (ru) [1,3]ДИАЗИНО[5,4-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ HER2
HK40081106B (en) [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
HK40081106A (en) [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
HK40039222B (en) Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
HK40039222A (en) Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22826087

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2024532456

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022826087

Country of ref document: EP

Effective date: 20240701

WWE Wipo information: entry into national phase

Ref document number: 202280089389.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 18715145

Country of ref document: US